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SOMMARIO 
INTRODUZIONE: Il mieloma multiplo (MM) è una neoplasia ematologica 
incurabile caratterizzata dallo sviluppo di farmacoresistenza intrinsica o 
mediata dalle cellule stromali midollari (BMSCs). Nelle cellule di MM, il 
pathway di Notch può essere iper-attivato a causa dell’iper-espressione dei 
ligandi Jagged oppure di una trans-attivazione di Notch2 dovuta ad una 
deregolazione dei fattori trascrizionali MAF. Il microambiente midollare, 
dove si localizzano le cellule di MM, può contribuire all’aberrante 
attivazione della via di Notch grazie alla presenza dei ligandi, espressi dalle 
BMSCs, oppure attraverso diversi stimoli, tra cui l’ipossia. Diverse evidenze 
in letteratura dimostrano come l’ipossia e il pathway di Notch siano in grado 
di supportare le cellule staminali tumorali (CSCs), che sono una 
popolazione cellulare intrinsicamente farmacoresistente e sono spesso 
causa di sviluppo di recidive nei pazienti. Nel MM sono state descritte le 
cellule staminali tumorali di MM (MM-SCs) come cellule aventi fenotipo 
CD138-. 
SCOPO: Lo scopo di questo lavoro è stato quello di valutare l’effetto 
dell’iper-attivazione del pathway di Notch sulla farmacoresistenza 
intrinseca e mediata dalle BMSCs nel MM; inoltre ho valutato l’effetto 
dell’ipossia sul pathway di Notch nelle MM-SCs. 
METODI: Per gli esperimenti, ho utilizzato due linee cellulari umane di MM, 
OPM2 e U266, che sono state coltivate in singolo o in co-coltura con la 
linea umana HS5 o la linea murina NIH3T3 per mimare le interazioni tra le 
cellule tumorali e le cellule stromali. Nelle co-colture, ho utilizzato la linea 
HS5-pGIPZ che esprime stabilmente la GFP per poter distinguere al 
citofluorimetro (FC) le due popolazioni cellulari. Per valutare il ruolo del 
pathway di Notch nella farmacoresistenza associata al MM, le linee cellulari 
di MM sono state silenziate per i ligandi Jagged1 e 2 utilizzando due 
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specifici siRNA (HMCL-JAG) o il controllo scrambled (HMCL-SCR) e trattate 
con Bortezomib, un farmaco usato comunemente nella terapia del MM; il 
tasso di apoptosi è stato misurato al FC come percentuale di cellule 
Annessina-V+. L’analisi dell’espressione genica è stata effettuata tramite 
RT-PCR quantitativa con primers specie-specifici per meglio caratterizzare 
il contributo delle cellule di MM (primers umani) e il contributo delle BMSCs 
(primers murini). Variazioni nell’espressione proteica di fattori anti-
apoptotici sono stati analizzati tramite FC. Gli studi ex vivo sono stati 
eseguiti su campioni primari di pazienti di MM: le cellule primarie di MM 
CD138+ sono state isolate immunomagneticamente dall’aspirato midollare, 
mentre le BMSCs primarie sono state isolate dalla frazione negativa, 
cambiando il terreno dopo 24h dalla semina. Le cellule primarie di MM 
CD138+ sono state trasdotte con un vettore lentivirale specifico per il 
silenziamento dei ligandi Jagged1 e 2, mentre le BMSCs primarie sono 
state colorate con un colorante lipofilico (PKH26) e poi co-coltivate con le 
cellule primarie di MM CD138+; le co-colture sono state trattate con i 
farmaci e al FC è stato misurato il tasso di apoptosi come cellule 
Annessina-V+. Per mimare una condizione di ipossia le cellule di MM sono 
state trattate con il cloruro di cobalto (CoCl2), per bloccare il pathway di 
Notch ho usato il DAPT che è un inibitore della γ-secretasi e inibisce il 
pathway di Notch. Per studiare le MM-SCs ho utilizzato come modello la 
linea cellulare umana di MM H929, che è stata caratterizzata 
fenotipicamente tramite FC per valutare variazioni nell’espressione di 
CD138 a seguito dei trattamenti con CoCl2, DAPT o la combinazione di 
entrambi. Per verificare l’effetto dell’ipossia sull’attivazione trascrizionale di 
Notch, ho utilizzato un sistema reporter in cui la linea cellulare umana 
HEK293 è stata trasfettata con un plasmide contentente una sequenza 
Notch-responsiva a monte della luciferasi e con plasmidi che codificano per 
le forme costitutivamente attive di Notch1 (ICN1) e Notch2 (ICN2); ho 
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misurato le variazioni dell’attività della luciferasi a seguito del trattamento 
con CoCl2.  
RISULTATI: I risultati ottenuti hanno dimostrato che il silenziamento dei 
ligandi Jagged1 e 2 influisce sulla biologia della cellula di MM, in particolare 
sulla farmacoresistenza intrinsica, causando una riduzione dell’espressione 
genica di proteine anti-apoptotiche quali BCL2, Survivin and ABCC1, 
BCLXL, SDF-1α, CXCR4 e quindi una maggiore sensibilità delle cellule di 
MM ai farmaci. Per quanto riguarda l’interazione delle cellule di MM con le 
BMSCs, ho potuto osservare che essi si attivano reciprocamente il pathway 
di Notch causando un’aumentata farmacoresistenza delle cellule 
neoplastiche dovuta a: i) un aumento dell’espressione genica di proteine 
anti-apoptotiche nelle cellule di MM; ii) il rilascio di fattori solubili da parte 
delle BMSCs, quali SDF-1α e VEGF che sono importanti per la crescita e 
sopravvivenza delle cellule di MM. Con i miei risultati ho dimostrato che il 
silenziamento dei ligandi Jagged1 e 2 nelle cellule di MM co-coltivate con 
le BMSCs, causa da un lato la diminuzione dell’espressione sia genica che 
proteica di fattori anti-apoptotici, e dall’altro riduce la capacità protettiva 
delle BMSCs, aumentato l’apoptosi delle cellule di MM trattate con farmaci. 
Gli stessi risultati sono stati confermati su campioni primari di pazienti di 
MM da cui sono state isolate sia le cellule di MM primarie CD138+ che le 
BMSCs primarie. Infine ho dimostrato, con un saggio reporter e trattamento 
con CoCl2, chel’ipossia è in grado di attivare il pathway di Notch; a seguito 
del trattamento con CoCl2, vi è un aumento delle MM-SCs e l’attivazione 
del signalling di Notch, stabilizzato da HIF-1α, è necessario per il 
mantenimento e l’amplificazione dell MM-SCs. 
CONCLUSIONI: I miei risultati ottenuti dimostrano come il silenziamento 
dei ligandi Jagged 1 e 2 sia in grado di ridurre la farmacoresistenza 
intrinsica delle cellule di MM e quella mediata dalle BMSCs; inoltre 
l’attivazione del pathway di Notch, indotta da HIF-1α, sia in grado di 
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sostenere le MM-SCs. Questi risultati dimostrano come il target di Notch 
possa essere un buon target terapeutico per contrastare l’insorgere di 
recidive nei pazienti di MM. 
ABSTRACT 
BACKGROUND: Multiple myeloma (MM) is an incurable hematological 
malignancy characterized by drug resistance, intrinsic or induced by bone 
marrow stromal cells (BMSCs). In MM cells, Notch pathway may be 
aberrantly activated due to the hyperexpression of Notch1, Notch2 or 
Jagged1 and 2 ligands. This effect may be attributed to genetic mutation 
only in part (i.e. translocations involving the MAF transcription factors may 
increase the transcriptional activity on their target gene Notch2). MM cells 
settle in the bone marrow (BM) and the BM microenvironment may be 
another player contributing to Notch signaling activation by triggering Notch 
receptors through BMSC-derived ligands or other stimuli including hypoxia. 
Indeed, recent evidences indicate that both hypoxic stimuli and Notch 
signaling activation are involved in cancer stem cell maintenance and self-
renewal, thereby contributing to drug resistance due to the resilience of this 
cancer subpopulation. MM stem cells (MM-SCs) have been characterized 
as a CD138- subpopulation.  
AIM: The aim of this study was to investigate the outcome of Notch 
signaling hyper-activation in intrinsic and BMSC-mediated drug resistance 
in MM cells and MM-SCs.  
METHODS: I assessed the effect of Jagged ligands by an inhibitory 
approach on MM cells. This was carried out by silencing Jagged1 and 2 
through specific siRNAs or lentivirally expressed shRNAs. The study got 
advantage of OPM2 and U266 cell lines and MM primary cells from 10 
patients. MM cells were cultured alone, to assess the effect of Jagged 
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silencing on intrinsic drug resistance, or co-cultured with BMSCs, to 
investigate the effect of Jagged inhibition on BMSC-mediated drug 
resistance. The BMSC models used were: i) the human HS5GFP+ cell line 
that, when cultured with MM cell lines, enabled a flow cytometric analysis of 
variations in drug resistance and anti-apoptotic proteins expressed by MM 
cells, along with changes in BMSC-production of pro-tumor cytokines (i.e. 
IL-6 and SDF-1a); ii) the murine fibroblasts NIH3T3. These cell lines mimic 
BMSCs and, when cultured with MM cell lines, enabled to confirm changes 
in key proteins by gene expression analysis through RT-PCR using 
species-specific primers to distinguish the contribution of MM cells (human) 
or NIH3T3 cells (murine); iii) experiments on primary CD138- MM cells 
were carried out using primary BMSCs stained with PKH26 as feeder cells. 
Intrinsic and BMSC-induced drug resistance was analyzed by challenging 
MM cells cultured alone or in co-culture systems with standard-of care 
drugs, i.e. Bortezomib. Apoptosis was assessed by detection of the 
percentage of AnnexinV+ cells through flow cytometry. Hypoxic BM 
microenvironment was mimicked by using cobalt chloride (CoCl2), while 
Notch pathway activation was inhibited using DAPT (a γ-secretase 
inhibitor). MM-SCs were analyzed in H929 cell line by flow cytometric 
analysis of the CD138- subpopulation. The effect of hypoxia on protein 
expression changes of Notch pathway members (i.e. Notch2 and Jagged1) 
was assessed by Western blot assay, while changes of Notch 
transactivation activity were assessed by dual luciferase Notch reporter 
assay in OPM2 cells and HEK293 cells. The high transfectability level of 
HEK293 cell line also enabled its transfection with multiple plasmids to 
assess the specific effect of CoCl2 treatment on the transcriptional activity 
of Notch1 and Notch2.  
RESULTS: The results of this work demonstrate that Jagged1 and 2 
increased expression levels affect MM cell biology maintaining high levels 
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of intrinsic drug resistance through the expression of anti-apoptotic genes, 
i.e. BCL2, Survivin and ABCC1, BCLXL, SDF-1α, CXCR4, with the 
consequent increase of MM cell sensitivity to standard-of-care drugs. 
Concerning the interaction of MM cells and BMSCs, MM cells stimulate the 
protective behavior of BMSCs, by inducing Notch activation through tumor-
derived Jagged1 and 2, with a consequent increase of drug resistance due 
to: i) release of pro-tumor soluble factors by BMSCs, i.e. SDF-1α and 
VEGF; ii) the induction of an elevated anti-apoptotic background in MM 
cells due to an increased expression of anti-apoptotic genes such as BCL2, 
Survivin and ABCC1. In vitro results were confirmed by co-cultures of 
primary MM cells. Finally, I verified that an hypoxic stimulus, mimicked by 
CoCl2, may be a cause of Notch activation in MM cells by increasing the 
transcriptional activity of Notch1 and Notch2, supposedly through 
interaction with HIF-1α that prevents ICN proteosomal degradation. Notch 
signaling activated by CoCl2 positively regulates the MM-SC population. 
The resilience that characterizes MM-SCs suggests that hypoxia-mediated 
activation of Notch signaling may be a further mechanism by which the BM 
microenvironment may induce the acquisition of drug resistance in MM.  
CONCLUSION: The evidences that Jagged1 and 2 silencing affects the 
intrinsic and acquired drug resistance in MM cells support the rationale for 
a Notch-tailored approach to overcome MM patients relapse.
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1. NOTCH PATHWAY 
1.1 Introduction 
In 1919 T.H. Mohr identified an haploinsufficient Drosophila Melanogaster 
strain that was characterized by “notched” wings. The gene responsible for 
that phenotype was named as Notch and was cloned for the first time in 
1985 (1). In humans, like other mammals, Notch family is formed by four 
homologue sequences named Notch1, Notch2, Notch3 and Notch4 which 
map, respectively, on chromosome 9, 1, 19 and 6, 
In 1991, Ellisen and colleagues identified the first ortholog Notch gene, 
Notch1 in patients with T-cell acute lymphoblastic leukemia (T-ALL) 
carrying traslocation t(9;7) (q34;q34.3) and it was called trans location-
associated Notch homologue-1 (TAN-1) (2). Notch family is formed by four 
receptor isoforms, Notch1-4, and two ligands family, Jagged ligands 
(Jagged1 and 2) and Delta ligands (Dll1-3-4) (3). 
Further studies demonstrated that Notch regulates many different biological 
processes such as morphogenesis, proliferation, apoptosis and cellular 
differentiation and it is fundamental for embryonic development of 
multicellular organisms (4). In mammals, Notch has a key role in regulating 
neurogenesis, gliogenesis, myogenesis, angiogenesis, haematopoiesis and 
in epidermal development (3). Notch is involved in adult tissue homeostasis 
promoting stem cell self-renewal, regulating cell fate (e.g. commitment in T 
cell or B cell lineage). 
Due to its important in regulating different cellular processes, Notch 
receptors or ligands mutation or deregulation are often associated to 
cancer burden, i.e. breast cancer, ovary, prostate, skin (5) and 
haematological malignancies: Notch1 deregulation is found in T-ALL, while 
Jagged2 deregulation in multiple myeloma (MM) (6) (7); Notch3 
deregulation correlates with CADASIL (cerebral autosomal dominant 
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arteriopathy with subcortical infarcts and leukoencephalopathy) onset (8) 
and Jagged1 with Alagille syndrome (3). 
1.2 Notch molecular structure (9) 
1.2.1 Notch receptor structure 
Notch is a protein with a molecular weight of 300 kDa. Notch is a single-
pass transmembrane protein formed by an extracellular subunity, a trans-
membrane domain and an intra-cellular subunity that are composed by 
(figure 1.2.1): 
• The extracellular domain is responsible for ligands binding thanks to 
Epidermal Growth Factor (EGF)-like repeats formed by a 
changeable number of repeats (29-36); Repeats 11-12 mediate 
receptor-ligand trans-interaction (receptor and ligands are 
expressed by two diverse cells), thus causing pathway activation; 
while repeats 24-29 are responsible for cis-interaction (receptor and 
ligands are expressed by the cells itself) and leads to Notch 
pathway blocking. Furthermore, there is a negative regulatory 
region (NRR) which prevents receptor activation without ligand 
interaction: NRR inhibits the first cleavage in S2 site thanks to its 
conformation structure that changes only after receptor-ligands 
interaction. 
• The transmembrane domain (TMD) which separate extracellular 
and intracellular portion 
• The intracellular domain is made by Recombination Signal Binding 
Protein for Immunoglobulin Kappa J Region (RBPj) association 
module (RAM) domain, which is fundamental for Notch-mediated 
transcriptional activation because is able to bind to the transcription 
factor CBF-1, Suppressor of Hairless, Lag-2 (CSL) and RBPj in 
mammals, promote the transcriptional complex assembly into the 
nucleus; one nuclear localization signal (NLS) followed by 7 Ankyrin 
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(ANK) repeats, that recruits nuclear proteins fundamental for 
transcription complex; two additional NLSs, responsible for nuclear 
trafficking and a motif rich in proline, glutamin acid, serine and 
threonine (PEST) at C-terminal of the protein. PEST domain 
regulates Notch receptor stability thanks to polyubiquitination 
signals that promote Notch proteosomal degradation. 
 
 
 
 
 
Figure 1.2.1 Notch receptors molecular structures (9). 
1.2.2 Notch ligands structure 
Notch ligands have a structure similar to those of receptors; they are 
classified in two families closely related: Delta ligands (Dll-1, 3, 4) and 
Serrate family (Jagged1, 2). Both ligands families are single-pass 
transmembrane proteins made by (figure 1.2.2): 
• Extracellular domain contains EFG-like repeats (6-16) and the N-
terminus (DSL) portion which is responsible for receptor binding and 
activation; Jagged family, if compared to Delta family, have twice 
repeats and a cysteine-rich (CR) region. 
• Intracellular domain (expect Dll3) contains multiple lysine residues 
that have a role in ligand activity; PDZ domain in included in 
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Jagged1, Dll1 and Dll4 ligands and is important for ligands 
interaction with cellular cytoskeleton and cellular adhesion. 
 
 
 
 
 
 
 
 
Figure 1.2.2 Notch ligands molecular structures (9). 
Among Notch ligands, Dll3 has a different structures because it has missed 
the region for receptor interaction and trans-activation: Ladi and colleagues 
demonstrated a possible inhibiting role for Dll3, indeed they demonstrate 
that, in mammals, Dll3 overexpression causes Notch signalling blocking 
(10). 
1.3 Notch signalling activation 
Notch is synthetized in the endoplasmic reticulum (ER) as single 
polypeptide (pre-NOTCH) formed by extracellular and intracellular domain. 
The O-fucosyltransferase (OFT1) is necessary for transporting pre-NOTCH 
from endoplasmic reticulum to Golgi apparatus, where the extracellular 
domain undergo fucosylation on Serine and Threonine residues (11). Pre-
NOTCH is cutted by a furin-like convertase in S1 site leading to the 
formation of a heterodimer composed by extracellular domain and TMD 
bound by non covalent bonds (12). Before reaching the cellular membrane, 
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Notch extracellular domain is glycosylated thus allowing receptor-ligands 
interaction and influencing ligand specificity (13). 
 
 
 
 
 
 
 
Figure 1.3 Notch receptors synthesis (9). 
Upon ligands interaction, there is a conformational change in NRR domain 
that allow to a A Disintegrin and Metalloproteinase 10 (ADAM10) to exert 
its proteolytic activity in site S2: the result is a truncated peptide that is still 
anchored to membrane and recognized by γ-secretase complex which 
cleaves the single-pass transmembrane portion of Notch. The γ-secretase 
complex is a multi-complex protease formed by three enzimes: Presenilin-1 
or 2 (PS1, 2), Nicastrin (NCT), anterior pharynx-defective 1 (Aph1) and 
Presenilin enhancer 2 (PEN-2); it recognizes the S3 region, between TMD 
and RAM domain and causes the release of active Notch intracellular 
domain (ICN) from the membrane (3). Active ICN migrates into the nucleus 
where, thanks to RAM domain, it interacts with CSL-RBPj transcriptional 
factor. If Notch signaling is switched off, the transcription factor CSL inhibit 
genic transcription in cooperation with co-repressor proteins like SMRT, 
SHARP, CIR1 and histone-deacetylases (14). Active ICN is able to 
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uncouple the complex that work as a co-repressor from RBPj and once 
RBPj is free, the formation of a tertiary complex with Master mind-like 
protein (MAML) and its co-activators happens (15); finally this big complex 
induce Notch target genes transcription. Notch1 intracellular domain (ICN1) 
is bound by a serine/threonine kinase Glycogen Synthase kinase 3-β 
(GSK3-β) that increase its stability (16); while, CDK8 kinase can 
phosphorylate nuclear ICN at PEST domain, thus causing the recognition 
of PEST domain by a E3 ubiquitin ligase, which mediate degradation of 
ubiquitinylated ICN by proteasomal machinery (17). 
 
Figure 1.3.1 Notch transcriptional complex (18). 
The transcription CSL-dependent is responsible for most of the effects 
mediated by Notch, but there are evidences in literature that there is also a 
CSL-independent Notch pathway activation (19). Deltex, that is a zync-
finger protein, regulates genic transcription in the CSL-independent 
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pathway and it interacts with the ANK domain in the ICN. In Drosophila 
Melanogaster models, but not in mammals, Deltex is a positive regulator of 
Notch pathway and the hypothesis is that it antagonizes p300 and it 
reduces genic expression and regulates the expression of particular 
transcription factors like E47. It seems that ICN itself regulates Deltex 
expression level (19). 
1.4 Notch pathway regulation 
Notch signalling is fine-tuned: both receptors and ligands are in dynamic 
equilibrium between “membrane pool” and “intracellular pool” included in 
vescicles. Because its relevance, Notch undergoes different modification 
during its maturation process (figure 1.4). 
In the ER, the O-fucosyltransferase 1 (POFUT1) catalyzes the addition of 
an O-fucose to serine and threonine residues in Notch extracellular 
domain. POFUT1 can act also as ER chaperone (11) and mediates Notch 
receptor translocation from ER to Golgi. The adding of the O-fucose on 
EGF repeats increases Notch-Dll binding and decreases Notch-Jagged 
binding, by altering Notch affinity to ligands presented by adjacent cells (11, 
20). 
In the cytoplasm, Notch pathway is regulated by Numb and Deltex: Numb 
is an adapter protein involved in the endocytosis process of Notch in 
combination with α-adaptin and Exp-15 and, as shown in different 
Drosophila and human models, it can inhibit Notch with different 
mechanisms: 
• By binding and activating Itch, which belongs to ubiquitin E3 ligase 
family and mediated ICN poly-ubiquitination and proteasomal 
degradation (21). 
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• By promoting the S2-cleaved Notch endocytosis before the γ-
secretase cut and ICN1 release. It works in collaboration with the 
AP2 domain of α-adaptin and NAK (Numb Associated Kinase) (22). 
• By preventing SANPODO gene product localization, that promotes 
Notch signaling (21). 
The role of Deltex has been discussed above. 
In the nucleus, Sel-10, Notch regulated ankyrin repeat protein (Nrap) and 
MSX2-interacting nucleat target protein (Mint) regulate Notch pathway. 
Sel-10 is a E3 ubiquitin ligase which binds ICN and recruits Skp1-Cullina-F-
Box (SCF) complex, thus causing Notch ubiquitination and its degradation 
by proteasomal machinery; Sel-10 regulation requires PEST domain to be 
hyper-phosphorilated by Cyclin-dependent kinase 8 (CDK8); CDK8 hyper-
phosphorilates PEST domain after transcriptional activation by binding of 
MAML to p300 (23). 
Nrap can bind CSL-ICN complex to two ANK domains and can either 
inhibits the complex or destabilizes ICN; Mint inhibits Notch pathway by 
blocking ICN bound to CSL and the ability of ICN to active transcription 
(24). The best characterized mechanism by which Notch is degraded is the 
one mediated by proteasome and by two E3-ubiquitin ligase (Itch and Sel-
10), but often the lysosome pathway is preferred: c-Cbl, an ubiquitin ligase, 
is the key mediator of lysosomal Notch degradation, indeed it binds Notch 
after a phosphorylation on tyrosine residue in the PEST domain (25). 
Notch signaling regulation involves also ligands expression and activity 
modulation, which is controlled by different mechanisms: EGF repeats in 
the extracellular domain undergo O-fucosylation that is subsequently 
modified by Maniac Fringe (MFNG) (26), thus regulating directly the 
receptor affinity for specific ligands family. 
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In addition, ADAM can cut ligands in juxamembrane region thus causing a 
reduction in the number of ligands available for receptor binding (27). Even 
for ligands, the combined action of ADAM and γ-secretase complex cause 
the release of ligands intracellular portion that can translocate to the 
nucleus (28): it is not yet well dissect the mechanism but it seems to 
regulate ligands availability and their possible intracellular activity. 
Ligands have a ubiquitination regulation, as for receptors, and the 
ubiquitination of multiple lysine residues is involved in this process (29). 
There are other molecules that can directly interact and influence ligands 
expression (30): Vascular endothelial growth factor (VEGF) (31); 
transforming growth factor β (TGF-β) and platelet derived growth factor 
(PDGF) (32) (33); WNT signaling (34).	  
Some evidences demonstrate that the formation of an in-cis inhibition 
complex occurs if both receptor and ligand are in the membrane of the 
same cell. This mechanism is fundamental in limiting Notch activity area 
and it determines if the cell can send signal (ligands are more abundant) or 
if the cell can receive the signal (receptors are more abundant) (35). It has 
been reported that ligands and receptors can be segregated into different 
membrane sub-domains inducing either reception or signal transmission 
(36). 
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Figure 1.4 Notch pathway regulation. 
1.5 NOTCH TARGET GENES 
Despite signals mediated by Notch pathway has different results, it has 
been identified only few Notch target genes in a variety of cellular context. 
Hairy and enhancer of split (HES) family genes are the most studied and 
well characterized Notch target in Drosophila; the HES family is conserved 
during evolution and, in mammals, correspond to HES (1-7) genes and Hey 
(1, 2, L) family genes that are transcriptional factors with a helix-loop-helix 
conformation that act as transcriptional repressors. Among Notch target 
genes there are: 
• Negative regulators of the pathway itself (NRARP and Deltex-1). 
• Oncogenes (c-myc, cyclinD1, p21/Waf1). 
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• Genes involved in T-cell maturation and in Th1/2 lineage 
differentiation (IL2-R, preTa, GATA3). 
• Transcription factors (HoxA5, 9, 10 and NFkB2) 
• Anti-apoptotic protein coding-genes (bcl-2) 
• NOTCH1 and NOTCH3. 
 
1.6 THE ROLE OF NOTCH SIGNALLING IN CANCER 
Notch pathway, as previously said, is involved in different biological 
processes and controls many cellular function, like cell cycle (37), cell 
differentiation and metabolism (38). Because of its relevance, pathway 
alteration or deregulation result in cell transformation and tumor burden. 
Interestingly, Notch can’t be defined as an oncogene or a tumor suppressor 
because its outcome is tissue-specific or depends on the cellular type. 
Table 1.6 Notch as oncogene or tumor soppressor in many cancers (5). 
1.6.1 Notch as oncogene 
Notch pathway deregulations occur either in solid tumor (breast cancer, 
melanoma, neuroblastoma, prostate cancer (39)) or haematological 
malignancies (leukemia (40), multiple myeloma (41)). From 90s up-to-date, 
Notch signalling aberration correlate with haematological malignancies like 
T-ALL, acute myeloid leukemia (AML) and multiple myeloma (MM). In T-
ALL, that is an aggressive neoplasia of immature T cells, it has been 
C2C12 cells upon serum withdrawal, and this is likely to occur by
inhibiting the function of the muscle-specific transcription factor
MyoD [20].
2. Enzymatic modulation of Notch pathway
One characteristic of Notch signaling is the involvement of
multiple enzymatic modulations, which serve to regulate Notch
signal transduction. Besides ligand-triggered, metalloprotease and
g-secretase-mediated proteolytic cleavages, and furin-mediated
Notch maturation, Notch signaling can be regulated by four E3
ligases (Su(dx)/Itch, Sel-10, Neutralized, and LNX (ligand of Numb-
protein X)) to undergo ubiquitination and subsequent proteolysis.
Notch endocytosis by a different class of E3 (Nedd4) promotes the
degradation of Notch whereby activation of the Notch signaling is
attenuated/terminated [21–24]. LNX also can ubiquitinate the
Numb, a Notch antagonist for degradation, which enhances/
stabilizes the Notch pathway activation [25,26].
Moreover, Notch rec ptors are post-translationally modified by
glycosylation [27] and phosphorylation [28], adding further
complexity to the regulation of Notch signaling. The Notch
receptors can be glycosylated extracellularly at the EGF-like
repeats. Enzymes that process the extracellular post-translational
modification include the glycosyltransferase Fringe and O-fucosyl
transferase 1 (O-Fut). Fringe enzymes addN-acetyl-glucosamine to
the O-linked fucose to inhibit the binding of Notch receptors to
Jagged. In contrast, Fringe potentiates Delta-initiated Notch
activation [29]. The mechanism underlying such a ligand-
dependent regulatory effect remains unclear. The Notch protein
is phosphorylated variably on serines of the cytoplasmic domain
[30]. The phosphorylated NICD can preferentially associate with
Su(H). Formation of NICD/Su(H) complex may determine the
subcellular location of NICD [28]. The studies of Notch post-
translational modification by enzymes provide both a direction for
further elucidation of the mechanisms that regulate Notch
activation, and a new paradigm for the role of enzymatic
modifications in Notch-related diseases, especially cancers.
3. Notch signaling in cancer and angiogenesis
Notch signaling is one of the critical pathways in embryonic
development and patterning. Given tha tumorig nesis and organ
development are believed to share similar mechanisms, it is not
surprising that developmental pathways, such as Notch, Wnt, and
Hedgehog are employed by tumor cells for their development and
progression. Highly aggressive tumor cells have been shown to
carry many characteristics of embryonic progenitor cells and use
the Notch signaling pathway to promote their survival. Dysregula-
tion of the Notch pathway has been associatedwith awide range of
cancers [31–33]. The Notch pathway could be either oncogenic or
tumor suppressive depending on the tissue and organ site in which
it is expressed (Table 1). However, how does activation of a single
pathway give rise to two opposite outcomes in different cell types
and contexts remains to be a mystery. One explanation for this
seemingly paradoxical response is that canonical Notch pathway
turns on/off different tissue/cell-specific target gene(s) or down-
stream pathway(s) which determines ultimate effect of Notch
signaling. For example, in keratinocytes, perhaps CSL only binds
the p21 promoter therebyNotch functions as a tumor suppressor in
this type of cells. Another potential explanation is that it depends
upon other cooperative signaling(s). For instance, Notch1-deficient
mice develop spontaneous, highly vascularized basal-cell carci-
noma (BCC)-like tumors. In both mouse and human, BCC is
frequently associated with deregulated Hedgehog (Shh) signaling,
and Notch1-deficiency in the mouse skin leads to increased Gli2
expression, which is a downstream component of the Shh pathway
[34]. Another pathway that seems to be deregulated as a
consequence of loss of Notch1 is Wnt pathway, which results in
increased b-catenin-mediated signaling in hyper-proliferative
skin and primary tumor lesions, suggesting that Notch might
suppress Wnt signaling in the skin [34]. The cross-talk between
these pathways comprehensively determines the identity and
threshold of downstreampathway(s)which controls cell fate.With
respect to the different roles of Notch in cancers, further studies are
needed to specifically identify the underlying mechanisms.
The general mechanisms of deregulation of Notch signaling
characterized in cancers include chromosomal translocation (t (7,
9)) resulted constitutive expression of NICD [35], gain-of-function
mutations in Notch1 in human T-cell acute lymphoblastic
leukemia (T-ALL) [36], gene amplification of Notch3 in ovarian
serous carcinoma [37], and the low levels of the Notch antagonist
Numb in human breast cancers [38]. One main difficulty in the
Notch study is to address how this simple, direct pathway gives
rise to two opposite effects in different cell types and contexts. This
review recapitulates the recent studies about the multi-functions
of Notch and the potential therapeutic implications in cancers.
4. Notch in hematologic l tumors
Notch activation has been implicated in tumorigenesis of
various hematological diseases, including leukemias, lymphomas,
and multiple myeloma. In 1991, it was discovered that the
Table 1
Involvement of aberrant Notch signaling in awide variety of cancers. Notch signalingmay act as a tumor suppressor or a promoter depending on the cell type and cell context.
Tumor type Notch/ligand Function Reference
T-cell acute lymphoblastic leukemia (T-ALL) Notch1 Oncogenic [37]
Acute myeloid leukemia (AML) Jagged1 Oncogenic [45]
B-chronic lymphocytic leukemia (B-CLL) Notch1, Notch2/Jagged1, Jagged2 Oncogenic [46]
Diffuse large B-cell lymphoma Notch2 Oncogenic [48]
Marginal zone lymphoma Notch2 Oncogenic [49]
Multiple myeloma (MM) Notch1, Notch2/Jagged1 Oncogenic [50,52]
Precursor B-cell acute lymphoblastic leukemia (pre-B-ALL) Notch1–4 Tumor suppressive [51]
Cutaneous squamous cell carcinoma (SCC) Notch1 Tumor suppressive [56]
Melanoma Notch1 Oncogenic [33,57–59]
Breast cancer Notch4, Notch1, Oncogenic [61,63,65]
Human breast cancer Notch2 Tumor suppressive [64]
Human breast cancer Notch1/Jagged1 Oncogenic [66]
Non-small cell lung cancer (NSCLC) Notch3 Oncogenic [70,71]
Adenocarcinoma of the lung (ACL, a type of NSCLC) Notch1/Jagged1, Dll1, Dll4 Tumor suppressive [72,73]
Small cell lung cancer (SCLC) Notch1/2 Tumor suppressive [74,75]
Colorectal cancer (CRC) Notch1/Jagged1, Jagged2, Dll4 Oncogenic [84–86]
Pancreatic cancer Notch1, Notch3/Jagged2, Dll4 Oncogenic [87–89,91]
Glioblastoma Notch2 Oncogenic [93]
L. Yin et al. / Biochemical Pharmacology 80 (2010) 690–701692
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demonstrated that 60% patients are carrying Notch pathway mutations that 
are able to accelerate disease progression (40). In AML, the role of Notch 
pathway is not well characterized, but my group published a work 
demonstrating that in AML primary sample, Jagged1 expression was high 
even if Notch pathway was partially active (42): these findings suggest that 
may occur a pathway activation ligands-mediated and Notch independent 
(43). The role of Notch pathway in MM will be discuss in the next chapter. 
In breast cancer, is evident how Notch pathway has an oncogenic role: 
indeed the overexpression of Notch4 activates transforming growth factor-β 
(TFG-β) and hepatocytes growth factor (HGH) signalling pathway, 
promoting tumor invasion in ductal breast carcinoma (44). In human 
cervical cancer, Notch is aberrantly activated by either the accumulation of 
Notch1 and Notch2 or by Jagged1 expression: the final result is activation 
of PI3K/AKT pathway and Myc upregulation (45). 
1.6.2 Notch as tumor soppressor gene 
There are evidences showing that Notch signaling can act as a tumor 
suppressor; but the mechanism is still not well defined and new data 
demonstrate that it is probably tissue and time specific. Rangarajan and 
collegues well demonstrate that in keratinocytes, Notch signaling controls 
cell cycle and its activation causes a block in cell proliferation and cell cycle 
arrest: this effect is mediated by p21 and p27 upregulation and inhibition of 
Wnt pathway by β-catenin (46). 
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2 MULTIPLE MYELOMA 
2.1 INTRODUCTION 
Multiple myeloma (MM) is a malignant disorder of plasma cells that 
accounts for approximately 11% of hematologic malignant disorders. The 
annual age-adjusted incidence is 4,3/100000/year, with 30330 estimated 
new cases in 2016 in the US (47). This type of cancer is characteristic of 
the elderly, and the average age at diagnosis is 66 years, with only 2% of 
patients that are younger than 40 years (48). Despite the introduction of 
new drugs and the development of new clinical protocols, MM is still an 
incurable disease, with a survival rate at 5 years of 49% 
(http://seer.cancer.gov/csr/1975_2013/). The most common symptoms in 
MM are fatigue and bone disease (bone pain and osteolytic skeletal 
lesions), which are present in 80% of patients. Other recurrent symptoms 
are anemia, immunodeficiency and decreased renal function due to Ig 
precipitation. Multiple myeloma is now considered as the evolution of 
Monoclonal gammopathy of undetermined significance (MGUS), an 
asymptomatic condition that is estimated to be present in 3-4% of the 
general population older than 50 years (49) (50), from which develops due 
to pathogenic events at a rate of 1%/year (51).  It represents a phase of 
asymptomatic expansion of clonal plasma cell that can be clinically defined 
by the presence of a percentage of clonal plasma cells 
(CD19−/CD56+/CD45−/CD38+) <10% of all bone marrow mononuclear cells, 
by the absence of end organ damage and by a concentration of Ig in the 
serum lower than 3 g/dl. The passage from MGUS to MM is clinically 
defined by an increase in the percentage of malignant plasma cells, that 
exceeds 10%. MM, depending on the presence or not of any other 
characteristic symptoms, can be further classified in smoldering 
(asymptomatic) MM and symptomatic MM. Early stages MM cells present a 
high dependency on the supportiveness of the bone marrow 
microenvironment, in particular of the bone marrow stromal cells (BMSCs). 
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MM cells interact directly with these cells, or can benefit of the release of 
pro-tumor soluble factor (i.e. IL-6). During disease progression, however, 
tumor cells acquire independency from the surrounding microenvironment, 
being now able to migrate outside the bone marrow, generating extra-
medullary lesions (plasmacytoma) or becoming leukemic (plasma cell 
leukemia, PCL) at terminal stages. 
2.2 MM PATHOGENESIS 
MM is a neoplasia with different stages and each one is characterized by 
an acquired genetic alteration within MM cells, thus causing alteration of 
important signalling pathways. These steps can be distinguished in: 1) 
transformation of normal plasma cells to MGUS; 2) progression of MGUS 
to MM; 3) final evolution to extra-medullary diseases (figure 1) (52). 
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Figure 1: Progression of multiple myeloma (52). 
Recent data obtained from analyses conducted with advanced genetic 
techniques have shown that disease progression from MGUS to MM is not 
necessarily direct, since in certain cases MM originates as a de novo 
condition. 
B-cells, during their maturation process, go through two different rounds of 
genomic rearrangement regarding light and heavy chains. In the germinal 
centre of the secondary lymphoid organs, B cells rearrange heavy chains 
by interacting with dendritic or T cells in an antigen-dependent manner and 
becoming plasmacells secreting immunoglobulins upon antigens 
presentation (53) (54). Plasmacells arrest their cell cycle in the G0/G1 
phase and either remain in the lymph nodes as memory B-cells or return to 
the BM as long-lived plasmacells. The first genetic alteration which gives 
rise to MM, should regard cell cycle machinery, because plasmacells within 
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the BM have a really low proliferative rate. The hypothesis is about the fact 
that there could be two distinct mechanism regulating cell cycle 
abnormalities inducing plasmacells proliferation, in particular cyclin D 
family. The first mechanism comprises the arise of recurrent chromosomal 
translocations in the immunoglobulin heavy chain (IgH) locus at 14q32 (55). 
The most frequent chromosomal translocation is t(11;14)(q13;q32), 
observed in 15–20 % of MM cases (56), followed by t(4;14)(p16;q32), with 
a 12–15 % prevalence (57, 58). Other more rare translocations, including 
t(14;16)(q32;q23), t(14;20)(q32;q11), and t(6;14) (p21;q32), have a 
frequency <5 % (59). Each of these translocations induce the regulation of 
the cyclin D1: 
• t(11;14)(q13;q32) translocation causes cyclin D1 overexpression 
gene located in 11q13 because it is controlled by (60). 
• t(6;14)(p21;q32) translocation induces cyclin D3 gene at 6p21 
overexpression (61). 
• t(4;14)(p16;q32) translocation induces the upregulation of the 
histone methyltransferase MMSET (also known as 
WHSC1/NSD2/KMT3G), which modify the methylation profile of the 
genome, increasing the levels of H3K36me2, thus causing aberrant 
expression of cyclin D2 (62) (63). 
• t(14;16)(q32;q23) and t(14;20)(q32;q11) Translocations upregulate 
Maf family transcription factors C-MAF and MAFB, two transcription 
factors that can increase transcription levels of the cyclin D2 (63) 
(62). 
 
The second mechanism, that happens in the stage of malignant 
transformation of plasmacells to MGUS, is hyperdiploidy and is observed in 
up to 55 % of MM patients, and is overlapping with the presence of 
translocation of the 14q locus in 10 % of MM cases (64). For still unknown 
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reasons, hyperdiploidy induce a gain of the odd-numbered chromosomes 
3, 5, 7, 9, 11, 15, 19, and 21, but it is known that in trisomy 11, 
hyperdiploidy (approx. 30 %), may derive from an overexpression of the 
cyclin D1 due to an increase in gene expression. In the stage from MGUS 
to MM, there is an increased percentage of malignant cells resident in the 
BM, because they have accumulate genetic alteration, causing an 
increased proliferation rate; the two major pathways involved in this 
process are the oncogenic Ras and Myc, as indicated by an increased 
frequency of the point mutations of K-Ras and N-Ras (7 % in MGUS to 24–
27 % in MM) (65, 66). Evidences from literature demonstrated that, during 
MM progression from MGUS to MM, MM cells carrying t(11;14) 
translocation, carry the deletion of chromosome 13, causing an 
haploinsufficiency of the retino-blastoma (RB) tumor suppressor gene at 
13q14, inducing cell proliferation and disease progression (67). In the final 
stage of the disease, named as plasmacells leukemia (PCL), MM cells 
become independent from the BM microenvironment: MM cells reach blood 
circulation and inducing lesions in other organs. PCL stage occurs even 
because NFkB pathway is constitutively activated (68) and another feature 
is the presence of chromosomal abnormalities, involving e.g. deletion of 
17p13 locus inducing p53 inactivation. 
2.3 MM THERAPY & DRUG RESISTANCE 
MM is still an incurable disease despite the development in recent year of 
many new drugs and therapeutic protocols. MM patients at diagnosis are 
divided into different groups based on their age, their category of risk, the 
presence of eventual comorbidities or other limiting factors that could 
interfere with the treatment. For newly discovered patients the most 
diffused approach consists of an initial period (4 months) of treatment with 
three different classes of compounds (proteasome inhibitors, 
immunomodulatory drugs, corticosteroid) and to which follow the 
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autologous hematopoietic stem cell transplantation. Due to the risk of toxic 
and/or fatal complications related to the transplantation, this approach is 
offered only to patient younger than 65 years. These patients, after an 
initial treatment with the “VRd” protocol (bortezomib, lenalidomide, 
dexamethasone), undergo the “induction chemotherapy” to release the 
stem cells into the blood flow. After that stem cells have been collected, a 
new more potent high dose round of chemotherapy is executed in order to 
kill most, but not all, the tumor cells. Once the treatment has been 
complete, stem cells are injected back to the patient to allow bone marrow 
regeneration. This approach does not cure multiple myeloma, but increase 
overall survival. However, only a small percentage of patients at diagnosis 
can be treated with this approach. These non-transplantable patients are 
usually treated with the same regimen “VRd” for longer periods. 
As previously said, different classes of drugs have been released in recent 
years: 
• Chemotherapics (Melpahalan) 
• Corticosteroids (Dexamethasone); 
• Immunomodulating agents (lenalidomide, thalidomide, 
pomalidomide) 
• Proteasome inhibitors (Bortezomib, Carfilzomib, Ixazomib). 
 
Despite these innovations in MM therapy, MM patients will develop 
resistance to treatment at a certain point due to the presence of both 
intrinsic and environmental mechanisms that induce drug resistance. 
Indeed, together with mechanisms activated by the presence of genetic 
abnormalities, i.e. p53 mutations or deregulation of the NF-κB pathway, 
interactions of multiple myeloma cells with the surrounding 
microenvironment can induce drug resistance. Soluble factor-mediated 
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drug resistance (SFM-DR) and cell-adhesion mediated drug resistance 
(CAM-DR) are the two complementary mechanisms induced by cell 
adhesion that have been shown to prevent cell death (69) (70). SFM-DR 
can be explained by involvement of IL-6, the main cytokine in MM, that, 
through macrophage inflammatory protein-1α (MIP-1α) can foster cell 
survival by enhancing adhesion of myeloma cells to bone marrow and 
fibronectin. On the other hand, adhesion of MM cells to BMSCs or ECM 
proteins by β1 integrins mediate CAM-DR. When myeloma cells adhere to 
fibronectin, they become resistant to multiple drugs, including doxorubicin 
and melphalan (71). However, different types of ECM components were 
altered in different drug resistant MM cells. For example, CAM-DR to 
doxorubicin, melphalan, vincristine, bortezomib and mitoxantrone has been 
induced in MM through adhesion to FN or BMSCs by VLA4 integrin (α4β1) 
and IEA-1 (72) (73). 
2.4 ROLE OF NOTCH PATHWAY IN MM 
Notch signaling is one of the key signaling pathway that results to be 
dysregulated in MM due to different mechanisms, some of them are still not 
completely elucidated: 
• NOTCH1 and JAGGED1 result to be overexpressed during disease 
progression, even if no known mechanism was reported; 
• A group of MM patients (approximately 6%) carrying the 
translocations t(14;16)(q32;q23) and t(14;20)(q32;q11) showed 
higher levels of transcription of the gene coding for NOTCH2, that 
result in an increased activity of the Notch pathway. This effect was 
due to the activation of the C-MAF and MAFB transcription factors 
induced by the translocation themselves (74). 
• An early complex event, that probably occur during the MGUS 
phase, involves different possible mechanisms and induces 
JAGGED2 deregulation. Three different mechanisms have been 
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proposed to explain JAGGED2 overexpression: hypomethylation of 
the promoter of JAGGED2; alterations in the expression of 
Skeletrophin, an Ubiquitin-ligase necessary for JAGGED2 activity; 
loss of SMRT/NCoR2 corepressor, resulting in JAGGED2 promoter 
acetylation and increased transcription (75). 
Overexpression of Notch related proteins in MM has as a first result the 
abnormal activation of the Notch signaling inside tumor cells themselves. 
This may derive from both homotypic interactions between nearby 
myeloma cells, as well as from the contact with surrounding stromal cells. 
The importance of the activation of Notch signaling in tumor cells is 
demonstrated by the effects resulting from the inhibition of the pathway: 
increase rate of apoptotic cells, decreased proliferation rate and higher 
sensibility to compounds that increase apoptosis (i.e. Bcl-2/Bcl-XL 
inhibitors) and to standard chemotherapics. An important result obtained by 
our laboratory, and confirmed both in vitro and in vivo, allowed us to link 
Notch pathway with the well-known CXCR4/SDF1α axis, that has been 
reported to play a crucial role in MM migration toward the bone marrow, as 
well as in promoting tumor survival and growth (76). For this reason, high 
activation levels of the Notch signaling in MM cells could be connected to 
an increased ability to migrate inside the bone, generating new lesions. In 
the last years, another crucial role for Notch signaling has been reported in 
cancer stem cell self-renewal. A role for the Notch pathway in the MM stem 
cells (MMSCs)-mediated effects has also been proposed on the basis of 
functional assays. Indeed MMSCs, for which there are not univocal marker 
since their origin is still a matter of debate, seems to play a role in drug 
resistance, tumor dormancy and relapse. Chiron and colleagues, on the 
other side, reported that JAGGED2 expression positively correlates with 
the spontaneous clonogenic growth of MM cells, while Jagged silencing in 
vivo impaired tumor growth (77). 
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Homotypic interactions between tumor cells are not the only interactions 
mediated by Notch receptors/ligands. As reported by Xu and colleagues, 
BMSCs express DLL1 that can engage with the NOTCH2 receptor present 
on the membrane of MM cells. Activation of the signaling cascade by 
NOTCH2 is then responsible for the upregulation of the gene coding for the 
CYP1A1 (cytochrome P450, family 1, subfamily A, polypeptide 1), a 
cytochrome involved in the development of resistance to treatment with 
bortezomib. An important outcome derived from the JAGGED2-mediated 
interaction between MM cells and BMSC is the increased secretion of 
soluble factors by the latter, including interleukin 6 (IL-6), vascular 
endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF1). 
These soluble factors act as pro-tumor soluble factors, exerting their 
function on tumor cell: 
• IL-6 is the major growth factor for MM cells, involved also in the 
development of resistance to dexamethasone in vitro; 
• VEGF has a double effect, by promoting MM cell growth and 
stimulating neo-angiogenesis; 
• IGF1 promotes survival in MM cell and development of bortezomib 
resistance. 
A paper recently published by our group revealed the effects of Notch 
signaling activation in the context of bone disease development, showing 
that Notch signaling activation in both MM cells and BMSCs stimulates the 
release of the major osteoclastogenic soluble factor, RANKL. Once 
released, RANKL engages RANK receptor in OCL progenitors that activate 
the osteoclastogenic NF-kB pathway; this in turn result in the increased 
expression of NOTCH2 receptor, that can interact with the Jagged ligands 
expressed by MM cells, activating Notch pathway in OCL progenitors too 
(78). Since osteoclast formation and the insurgence of bone lesions 
represent two processes in which are involved also OBLs, Zanotti and 
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colleagues analyzed the effects of Notch activation in OBL, demonstrating 
that it inhibits OBL differentiation. These results were then confirmed by an 
in vivo model, in which treatment with γ-secretase inhibitor reverted the 
inhibition of OBL maturation (79). 
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3. THE BONE MARROW MICROENVIRONMENT IN MULTPLE 
MYELOMA 
3.1 INTRODUCTION 
Different evidences find out in recent years, have shown that either 
different types of solid tumors or haematological malignancies depend from 
the surrounding microenvironment. MM localizes within the bone marrow 
(BM) and is strictly dependent from its microenvironment which is 
composed by different cell types and non-cellular molecules. The different 
cell types resident within the BM are: BM fibroblast-like stromal cells 
(BMSCs), vascular endothelial cells, hematopoietic stem cells (HSCs), 
progenitor cells, immune cells, erythrocytes, osteoclasts and osteoblasts. 
The non-cellular components, that is named as extracellular matrix (ECM) 
gives support to the cellular compartment and is composed by a variety of 
different proteins, i.e. fibronectin, collagen and laminin. 
 
Figure 2: MM bone marrow microenvironment (80). 
 28 
MM cells can directly interact with the BM microenvironment, thus causing 
the activation of different pathways and, as a consequence, influencing MM 
cells biology in term of cell growth, survival, migration, invasion and drug 
resistance. Furthermore, it is known that MM-associated comorbidities, 
such as osteclastogenesis, or the release of soluble factors crucial for MM 
cells are triggered by the interaction of neoplastic cells with either cellular 
and non-cellular compartments (7). 
3.2 ADHESION MOLECULES 
MM cells express on their surface different classes of integrins, that are 
adhesion molecules involved in MM cells contact with components of ECM, 
laminin, collagens and fibronectin; the integrin responsible for this 
interaction is the β1 integrin (81). MM cells express other types of surface 
proteins mediating their interactions with the BM microenvironment, among 
which is remarkable CD138, also known ad Syndecan-1. Adhesion 
molecules have a role, not only in mediating MM cells interaction with other 
cells, but also in drug resistance because they induced a phenomenon 
known as cell adhesion mediated drug resistance (CAM-DR), preventing 
MM cells drug-induced apoptosis (69). Bortezomib, a proteasome inhibitor 
and a commonly used drugs in therapy, overcame CAM-DR by selectively 
downregulating the very late antigen-4 (VLA-4) expression in MM cells (72). 
3.3 SOLUBLE FACTORS 
All the signals that MM cells receive and send within bone marrow niche, 
can be either secreted cytokines or proteins presented on cellular 
membrane of different cells resident in the BM: in both cases, they play a 
fundamental role in sustaining disease progression and in mediating 
several biological processes described above. Cellular interaction happen 
in both direction and, for this reason, MM cells can release soluble factors 
or express receptors stimulate cells of the BM, thus causing the 
establishment of a “self-sustaining loop” in which, MM cells “shape” BM 
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cells to release cytokines that sustain malignant cells progression. The 
main cytokines released by MM in the BM microenvironment are: 
• Tumor necrosis factor-α (TNFα) 
• Transforming growth factor-β (TGF-β). 
• VEGF, 
• Angiopoietin-1, 
• FGF-2 
• Matrix metalloproteases (MMPs). 
 
Moreover, “shaped” BM microenvironment cells secrete different cytokines 
such as IL-6, VEGF, Stromal derived factor 1 (SDF-1) (CXCL12), 
Hepatocyte growth factor-scatter factor (HGF-SF) and Insuline-like growth 
factor-1 (IGF-1). IL-6 is a secreted cytokine by BMSCs that has 
fundamental role in regulating MM cells biology; MM cells also express IL-6 
receptor (IL-6R) on the cellular surface, hypothesizing that can be an 
autocrine regulation of IL-6 production and uptake by MM cells. In the past, 
many published articles demonstrate that BMSCs were the major producer 
of IL-6 and in 1996, Chauhan and colleagues found out that MM cells-
BMSCs interaction can boost the secretion of IL-6 by BMSCs and IL-6 
transcription were regulated by NFkB pathway; they also demonstrated that 
different cytokines classes, e.g. IL-1α, IL-1β, TNFα and VEGF, can activate 
IL-6 transcription and secretion in bot MM or BMSCs cells (82). 
VEGF, a secreted growth factors by BMSCs and MM cells, induces 
malignant cells proliferation by activating ERK signalling and promotes MM 
cells migration by triggering protein kinase C (PKC)-dependent response 
(83), finally, it stimulates the expression of IL-6 microvascular endothelial 
cells and BMSCs (84). TNFα is a pro-infiammatory cytokine involved in 
bone resorption processes and is expressed by BMSCs and by MM cells. 
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TNFα effects dependd on the cellular context: in MM it promotes 
proliferation, expression of adhesion molecules (ICAM-1, VCAM-1 and 
VLA-4) and activation of the MAPK/ERK pathway; while in BMSC it induces 
IL-6 secretion, activation of the NF-κB pathway and expression of adhesion 
proteins (ICAM-1 and VCAM-1) (85). MM cells express metalloproteases 
(MMPs), that are zinc-dependent protease able to cleaved protein in the 
ECM, increasing the ability of neoplastic cells to migrate and inducing the 
releasing of growth factors trapped inside the ECM (86). 
3.4 SDF1α/CXCR4 AXIS IN MULTIPLE MYELOMA 
Chemokine family is a superfamily of proteins (6-14kDa) released by 
different cell types during the inflammatory processes and have 
overlapping functions. Chemokines have a role in different contexts, either 
pathological or physiological and are classified in two groups: the CXC 
family and the family CC. Secreted chemokines can bind to specific 
receptor, that is a G-protein 7-span transmembrane receptors (GPCRs), 
inducing their specific effects. The peculiar feature of chemokines family is 
that a receptor can bind different types of chemokines and a chemokine 
can bind to a variety of receptors. In MM, chemokines have a fundamental 
role in disease progression and, in particular, the SDF1α/CXCR4 axis is 
fundamental for MM cell homing in the BM, adhesion, growth and motility: 
BMSCs release SDF-1α that binds with CXCR4 receptor expressed by MM 
cells in the membrane. In literature, there are several evidences of the 
importance of this chemokine system in vitro and ex-vivo models: it has 
been observed that SDF-1α levels correlates with disease progression and 
that it was significantly increased within different areas of the BM where 
MM cells are more concentrated; furthermore, in in vitro systems, SDF-1α 
inhibition in BM-mesenchymal stem cells (BM-MSCs) caused a a 
downregulation of pathways associated with adhesion, migration and 
survival. When, in MM cells, SDF-1α binds to CXCR4 induces the 
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activation of P13K and ERK/MAPK pathways, and cytoskeleton 
modifications helping MM cells to migrate: regarding this Parmo-Cabañas 
and colleagues demonstrated that, in two different murine MM cell lines, 
SDF-1α acts as chemoattractant inducing an increased expression of 
MMP-9 that helps malignant cell migration and invasion (87). The integrin 
α4β1, known as VLA-4, has a role in promoting transendothelial migration 
of MM cells induced by SDF-1α stimulus, thus causing an increased MM 
cells adhesion CS-1/fibronectin and VCAM-1, thanks to sphingosine-1-
phosphate and the activation of the GTPase RhoA: RacI and RhoA, that 
belong to GTPase RhoA family, promote malignant cells migration or 
adhesion thanks to the presence of ROCK, a Rac1 and RhoA effector, thus 
causing actin polymerization and activation of LIMK, SRC, FAK and cofilin. 
Data from in vitro experiments as well as correlation studies on patients 
affected either by MGUS or by MM showed that SDF-1α have a role in 
angiogenesis. The hypoxia-inducible factor-2 (HIF-2) binds to SDF-1α 
promoter, increasing the levels of SDF-1α, as well as the expression of 
CXCR4 in MM primary cells and cell lines. Another SDF-1α receptor is 
CXCR7, that is expressed on the cellular surface of angiogenic 
mononuclear cells (AMCs): it is involved in trafficking and homing of AMCs 
to BM areas of MM growth and contribute to neo-angiogenesis; recent 
studies indicate that neo-angiogenesis can be a new therapeutical target to 
inhibit tumor growth at very early stages. SDF-1α has also a role in 
regulating osteoclastogenesis and bone resorption in MM. There are 
different findings supporting this hypothesys: first, SDF-1α levels positively 
correlated with bone resorption in MM patients; second, if an osteoclasts 
precursors culture is supplemented with SDF-1α, there in a motility and 
activation, as well as a positive variation in the number and the size of 
resorption pits. SDF-1α ability to control osteoclast differentiation might be 
mediated by Bruton tyrosine kinase (BTK). BTK, a protein involved in B-
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lymphocyte development and in osteoclastogenesis, may induce migration 
toward SDF-1 with the consequently homing in the BM. 
. 
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4. HYPOXIA 
Hypoxia is described as a state in which oxygen pressure is below a critical 
threshold (pO2 < 5 mmHg), thus reducing organs functions; it can be 
caused by different conditions: increased altitude, localized ischemia or in 
solid tumor the core is hypoxic. Hypoxia plays also physiological roles in 
mammals, regulating embryogenesis, erythropoiesis, angiogenesis and, at 
cellular level, switching aerobic to anaerobic metabolism and inducing the 
expression of proteins involved in cell death and apoptosis processes (88). 
 
4.1 HIF-1α PATHWAY 
Hypoxia inducible factor-1α is the master regulator of hypoxic response: it 
is a transcription factor formed by two subunits: HIF-α subunit which 
expression is regulated and HIF-β that is costitutively expressed (89). It has 
been described three different HIFα isoforms: HIF-1α, HIF-2α and HIF-3α; 
HIF-1α expression is ubiquitous while HIF-2α is tissue speficic (90). HIF-3α 
has double effect: it can bind HIF-1β to active transcription or it can act as 
HIF-1α dominant-negative inhibitor because it has a truncated inhibitory 
PAS domain that is a result of a splice variant (91). 
The well-characterized HIF-1α regulation is the mechanism mediated by 
ubiquitin-proteasome degradation and oxygen level is the sensor switching 
on this process. 
In aerobic state, HIF-1α is hydroxylated by specific prolyl hydroxylases 
(PDH1, PDH2 and PDH3) on two conserved proline residues located within 
the oxygen-dependent degradation (ODD) domain and the reaction 
requires oxygen to occur (92); under hypoxic condition, PDH activity is 
blocked, causing HIF-1α stabilization. 
HIF-1α hydroxylation causes binding of Von Hippel Lindau protein (pVHL) 
to ODD domain that creates the binding site of an E3 ubiquitin ligase 
complex (elongin C, elongin B, cullin-2 and ring-box 1) that poly-
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ubiquitinate HIF-1α inducing its degradation by the proteasomal machinery 
(93) (figure 4.1). 
The central role of pVHL is underlined in the Von Hippel Lindau (VHL) 
disease, in which VHL gene is inactivated, causing the development of 
highly vascularized tumours in the kidneys, retina and central nervous 
system (94). 
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Figure 4.1. Hypoxia pathway (94). 
 
4.2 HIF-1α TARGET GENES (88) 
HIF-1α binds to specific Hypoxia rensponsive elements (HRE) and 
activates transcription of more than 100 genes that are involved in adapting 
cell to hypoxia and regulate a variety of cellular processes: 
• Anaerobic metabolism: HIF-1α promotes switch metabolism to 
anaerobic condition; it promotes anaerobic glycolysis and 
upregulates the expression of glucose transporter (GLUT1 and 
GLUT3) and glycolytic enzimes. HIF-1α activation also stops Kreb’s 
cycle by upregulating pyruvate dehydrogenase kinase I. 
• pH regulation: the increased glycolysis causes a toxic intracellular 
acidosis due to the increased production of lactic acid and CO2. 
HIF-1is able to upregulate the expression of monocarboxylate 
transporter 4, which mediates lactic acid efflux, and of membrane-
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bound carbonic anhydrase IX, which catalyses the conversion of 
extracellular CO2 to carbonic acid (H2CO3). 
• Angiogenesis: HIF-1α target genes include several pro-angiogenic 
factors, among which there is vascular endothelial growth factor 
(VEGF); the major consequence is the formation of new blood 
vessels that can supply nutrients and oxygen. 
• Other responses: HIF-1α induces an increased erythropoiesis and 
has a role in changes in cell proliferation because it affects c-Myc 
expression; in solid tumor it promotes metastasis and its expression 
correlates with poor prognosis. 
 
4.3 HIF-1α & NOTCH PATHWAY (95) 
It is known from literature that Notch pathway and HIF-1α signalling interact 
but the mechanism of how this happens is not well characterized. 
Gustaffson and colleagues tried to elucidate how Notch and HIF-1α 
interact. They started to evaluate if hypoxia could upregulate the 
expression of Notch target genes and they find out that Hey2 and HES1 
mRNA was increased respectively in C2C12 cells and in neural stem cells; 
the activation of Notch target genes by hypoxia was a mechanism Notch 
mediated because, in hypoxic condition, there is the activation of reporter 
gene controlled by a Notch-responsive promoter. They hypothesized two 
mechanisms by which HIF-1α interacts with Notch pathway: on one hand, 
HIF-1α binds ICN thus preventing Notch from degradation and stabilizing 
Notch transcriptional activity (Figure 4.3). On the other hand, the authors 
proposed also that HRE sequences are contained in the promoter region of 
Notch target genes, Hey2, which directly binds HIF-1α only if Notch 
pathway is active. 
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Figure 4.3 ICN and HIF-1α interaction. 
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5. CANCER STEM CELLS 
5.1 INTRODUCTION 
In 1994, Lapidot et al. first described cancer stem cells (CSCs) in a AML 
study: they identified a population enriched with CD34+/CD38- cells by 
transplanting it in severe-combined immune deficient (SCID) mice (96). 
Nowadays, CSCs were described in different solid tumors, breast, brain, 
prostate, melanoma; and notably, researches find out that about 100 CSCs 
are sufficient to create tumor in non-obese diabetic/severe-combined 
immune deficient (NOD/SCID) mouse model (97). 
CSCs have the characteristic asymmetric division, which consist in 
generating one SC and one cell able to differentiate after division. 
Furthermore CSCs have self-renewal capacity, express specific surface 
markers and are intrinsically drug resistance thus causing patients relapse 
(98). There are two alternative theories about CSCs generation: the first 
hypothesized that CSCs originate from normal stem/progenitor cells that 
gain the ability to generate tumor by genetic mutations or environmental 
alteration (98); the other theory suggests that CSCs may arise from 
somatic cells which gain stemness-like property thanks to 
genetic/heterotypic alteration, i.e. epithelial-to-mesenchymal transition 
(EMT) (99) 
 
5.2 MULTIPLE MYELOMA CANCER STEM CELLS 
In recent years, several debates has been made whether MM stem cells 
(MM-SCs) really exist. Early studies in MM models demonstrated that only 
a minority percentage of MM cells are able of clonogenic growth (100). 
Matsui et al. first described MM-SCs as a population CD138-; treatment of 
CD138- population with drugs, Bortezomib, Dexamethasone and 
Lenalidomide, doesn’t affect their ability to form colonies, if compared to 
CD138+ counterpart. MM-SCs have an higher expression of ABCG2, a 
membrane pump involved in drugs efflux, thus explaining their intrinsic drug 
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resistance feature; finally if CD138- population were injected into 
NOD/SCID mouse model, they engrafted and CD138+ plasmacells were 
detectable (101, 102). 
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Multiple myeloma (MM) is the second haematological malignancy and 
despite new therapies and new drugs, such as, immunomodulator agents 
(Lenalidomide, Pomalidomide) it is still incurable with a 5-years survival 
fare of 49% (https://seer.cancer.gov/archive/csr/1975_2013/) and diagnosis 
occurs at a median age of 69 (103). MM cells localize within the bone 
marrow, where they interact with different cell types, among which bone 
marrow stromal cells (BMSCs) sustain malignant cell survival and mediate 
drug resistance: drug resistance is the major cause of patients’ relapse. 
Notch pathway is a highly conserved signalling that is involved in different 
biological processes and in cell-cell interactions; because its importance, 
Notch pathway deregulation are often associated to cancer burden (7). 
Evidences in the literature have shown that Notch pathway is involved in 
MM progression: MM cells overexpress Jagged ligands, thus causing an 
aberrant Notch pathway activation in surrounding cells, that can be either 
other MM cells (homotypic interaction), or, e.g. BMSCs or osteoclasts 
precursors (heterotypic interaction). The axis CXCR4-SDF1α has a crucial 
role in MM progression, regulating cells proliferation, drug resistance and 
bone marrow (BM) homing and correlates with poor prognosis (104, 105); 
furthermore, my group has previously demonstrated that CXCR4 is a direct 
Notch target gene and, by blocking Notch pathway with GSIs they 
observed a decreased CXCR4 expression at gene and protein level (76). 
Regarding MM, few genetic alterations at the basis of Notch pathway 
deregulation, but the importance of microenvironment for disease 
progression suggests that, there could be other factors affecting Notch 
pathway activation or receptors/ligands overexpression: among this, 
hypoxia is known to positively regulate Notch signalling (95). The BM 
microenvironment is hypoxic and both Notch pathway and HIF-1α 
signalling pathway sustain cancer stem cells. This population is intrinsically 
drug resistant and therefore responsible for disease relapse. 
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The aim of this work is to evaluate the role of Notch pathway in MM drug 
resistance. The first part of this research aims to investigate the outcome of 
Jagged ligands silencing in MM cell intrinsic drug resistance by analysing 
changes in: 
• MM cells sensitivity to drugs 
• Genic and protein expression of anti-apoptotic factors 
In the second part, I have analysed the effects of Jagged silencing in MM 
cells interaction with BMSCs. More specifically the following aspects have 
been assessed: i) the ability of MM cells to increase BMSCs-induced drug 
resistance; ii) changes in released soluble factors crucial for malignant cell 
survival and drug resistance and confirmation of their involvement, and iii) 
changes in the expression of anti-apoptotic factors in MM cells. 
The in vitro results have been confirmed in primary MM cells isolated from 
BM aspirates of MM patients. 
Finally, I have investigated the role of microenvironment in activating Notch 
signalling in MM cells, focusing on hypoxia and on its ability to increase 
multiple myeloma stem cell populations. 
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1. IN VITRO STUDY OF THE EFFECT OF JAGGED SILENCING ON 
INTRINSIC DRUG RESISTANCE OF MM CELLS 
MM cells show an overexpression of Jagged ligands that cause an aberrant 
activation of Notch receptors in malignant cells with a consequent effect on 
MM cells biology, for example drug resistance. In order to extend the 
investigation to the outcome of Jagged ligands overexpression on drug 
resistance, I carried out a RNA interference approach to knock-down 
Jagged ligands expression. Two different human MM cell lines (HMCLs), 
OPM2 and U266, were transfected with two siRNA specific for Jagged1 
and 2 every 48h and after 96h I analyzed the biological effect on. drug 
resistance, along with the variations in gene expression variation of Notch 
pathway members and others target genes involved in sensibility to 
apoptosis. 
1.1 Outcome on Notch signalling activity 
U266 and OPM2 cell lines were silenced twice every 48 h with 25 nM anti-
Jagged1 and 25 nM anti-Jagged2 siRNA (HMCL-JAG) or the respective 
scrambled control (HMCL-SCR). At 96h, I tested the effect on gene 
expression levels of Notch pathway members by quantitative real time PCR 
(qRT-PCR):  
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Figure 1.1. Analysis of gene expression after Jagged ligands silencing. 
Jagged 1/2 were silenced in U266 (A) or OPM2 (B) cell line for 96h and 
gene expression were analysed by qRT-PCR; HMCL-JAG  were compared to 
HMCL-SCR and GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) 
gene was used as housekeeping; HMCL-SCR =1. 
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Fold change is calculated by the 2-ΔΔCt formula (for details see “Material and 
Methods” section), error bars show standard deviation of three independent 
experiments. Statistical analysis performed by one tail t test; *=p<0.05. 
As shown in figure 1.1, Jagged 1 and 2 expression was specifically knock-
down by siRNAs transfection and Notch pathway activity is inhibited as 
shown by the down-regulation of two Notch target genes, HES1 and HES6 
(HES1=Hairy enhancer of Split 1; HES6=Hairy enhancer of Split 6). 
1.2 Effect on Bortezomib drug resistance 
Once assessed the efficacy of Jagged1/2 silencing in U266 and OPM2 
cells, I evaluated its biological effect on intrinsic Bortezomib (Bor)-drug 
resistance: Bor is a proteasome inhibitor used as front-line therapy in MM 
treatment. A set up of drug concentration was previously carried out and 
indicate the most appropriate concentration of 8 nM for Bor. To assess the 
outcome of Jagged1 and 2 silencing on MM cell drug sensibility, following 
96h of transfection, cells were treated for 24h with the reported drugs. At 
the end of the treatment, apoptosis levels were assessed by flow 
cytometric analysis using coloration with Annexin-V.   
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Figure 1.2. Jagged silencing affects intrinsic HMCLs drug resistance. U266 
(A) or OPM2 (B) cells. HMCL-SCR or HMCL-JAG were treated for 24h with 8 
nM Bortezomib. Apoptotic cell were measured by flow cytometry as 
Annexin-V+cells. Graph shows the mean values of 3 indipendent 
experiments and error bars show standard deviation. Statistical analysis 
was performed using ANOVA and Tukey’s post test: *=p<0.5; **= p<0.01. 
HMCL-JAG =J1/2 KD. 
As shown in figure 1.2, Jagged1 and 2 silencing affects MM cell sensibility 
to Bor: indeed, the apoptosis levels in U266 (A) or OPM2 cells (B) when 
Jagged ligands are silenced is significantly increased if both HMCL were 
treated with with Bor. This result suggests that Notch pathway may have a 
role in mediating intrinsic Bor drug resistance of MM cells and targeting 
Jagged ligands may increase the sensibility of MM cells to Bor. 
1.3 Effect on gene expression of anti-apoptotic factors 
To investigate the molecular effectors underlying Notch pathway ability to 
mediate intrinsic drug resistance of MM cells, I evaluated the effect of 
Jagged silencing on gene and protein expression of anti-apoptotic effectors 
including CXCR4 (CXCR4=C-X-C chemokine receptor type 4), BCLXL 
(BCL-XL=B-cell lymphoma-extra large), BCL2 (BCL2=B-cell lymphoma 2) 
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and ABCC1 (ABCC1=ATP-binding cassette subfamily C member 1) that 
have been demonstrated to be under Notch transcriptional control in 
different cellular settings. Indeed, Chiaramonte’s group previously 
demonstrated that chemokine receptor CXCR4, involved in the regulation 
of MM cell proliferation, apoptosis and migration, is also a direct 
transcriptional target of Notch (76). BCLXL, BCL2 and Survivin are anti-
apoptotic genes whose expression has been demonstrated to be regulated 
by Notch in different cells (106); finally ABCC1 (ATP Binding Cassette 
Subfamily C Member 1), also known as MRP-1 (multi-drug associated 
protein 1) is a multispecific efflux pump that plays a key role in cancer cell 
drug resistance due to its ability to transport many chemotherapeutic drugs 
out of the cells (107). Also ABCC1 and other efflux pumps are Notch 
transcription targets. 
Gene expression analysis is shown in figure 1.3: 
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1.3 Effect of Jagged silencing on gene expression of anti-apoptotic factors. 
Upon Jagged silencing, U266 (A) or OPM2 (B) cell lines the expression of 
anti-apoptotic genes was analysed by qRT-PCR. HMCL-JAG were compared 
to HMCL-SCR. GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) gene 
was used as housekeeping gene; HMCL-SCR=1. Fold changes were 
calculated by the 2-ΔΔCt formula (for details see “Material and Methods” 
section), error bars show standard deviation (SD) of three independent 
experiments. 
As shown, Jagged silencing is able to decrease the gene expression of all 
the anti-apoptotic factors investigated, thereby explaining at least in part 
the mechanism underlying Notch pathway involvement in MM cell drug 
resistance. 
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1.4 Effect on protein expression of anti-apoptotic factors 
The effect of knock down of Jagged ligands on anti-apoptotic proteins was 
also confirmed by assessing Survivin, ABCC1 and BCL2 protein variation 
by flow cytometry (figure 1.4): 
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Figure 1.4 Protein expression of anti-apoptotic factors in U266 or OPM2 
cells silenced for Jagged ligands. Histograms display the levels of BCL2, 
Survivin and ABCC1 analyzed by flow cytometry in HMCL-SCR (green lines) 
or in HMCL-JAG (red lines), and an isotype-matched control (gray line). 
Histograms are representative of 3 experiments with similar results. 
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As shown in figure 1.4, Jagged inhibition is able to reduce the anti-
apoptotic proteins Survivin, ABCC1 and BCL2. 
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2. IN VITRO STUDY OF THE EFFECT OF JAGGED SILENCING IN 
MYELOMA CELLS ON THE INTERACTION WITH BMSC. 
MM cells are established within the bone marrow where they interact with 
different cell types, among these BMSCs play a crucial role in sustaining 
malignant cell survival. My purpose is to investigate if the levels of Jagged 
ligands expressed by myeloma cell may affect its ability to interact with 
BMSCs and induce a pro-tumor behavior. The hypothesis is that MM cell-
derived Jagged might trigger Notch signaling in the same tumor cell 
resulting in the release of soluble factors that stimulate BMSC pro-tumor 
behaviour, or that, upon cell-cell contact, MM cell-derived Jagged may 
activate Notch signalling in the nearby BMSCs, and these in turn may 
stimulate the release of pro-tumor factors. To answer this question, I set up 
a co-culture system of MM cells and BMSCs to measure the ability of 
BMSCs to support MM cell drug resistance and verify if silencing Jagged1 
and 2 in MM cell may reduce the supportive ability of BMSCs. For this 
study, presented in section 2.1 and 2.2, I took advantage of two different 
co-culture systems: the first co-culture system was composed by HMCL-SCR 
or HMCL-JAG and the human BMSCs, HS5. HS5 cells were engineered to 
stably express GFP (HS5-GFP) and help the detection of the two cell 
populations by flow cytometry. The second co-culture system consisted of 
HMCL-SCR or HMCL-JAG (U266 or OPM2) and NIH3T3 cells to mimic the 
mesenchymal stromal cell component. This culture system was specifically 
used to carry out the analysis of the changes induced on gene expression 
by Jagged1/2 knock down. Indeed, the presence of human myeloma cells 
and murine stromal cells enabled to detect the cellular origin of the 
investigated transcript by qRT-PCR using species-specific primers.  
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2.1 Effect of Jagged-silenced MM cells on BMSC-induced 
Bortezomib drug resistance 
I analysed the effect of Jagged silencing in MM cells on BMSC-mediated 
drug resistance. MM cells were silenced for 96h, co-cultured with HS5-GFP 
for last 48h and treated for last 24h with 8 nM Bor. Apoptotic MM cells were 
measured by flow cytometry as Annexin-V+cells: 
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Figure 2.1 Effect of Jagged silencing on drug resistance induced by 
BMSCs. U266 (A) or OPM2 (B). HMCL-SCR or HMCL-JAG were co-cultured 
with HS5-GFP for 48h and treated with 8 nM Bor for last 24h. Apoptosis 
rate of MM cells were assessed by flow cytometry. Graph shows the mean 
values of 3 independent experiments and error bars show standard 
deviation. Statistical analysis was performed using ANOVA and Tukey’s 
post test: *=p<0.5; **= p<0.01. 
 
The results, shown in figure 2.1, demonstrate that HS5 cells can 
significantly protect co-cultured U266 cells from apoptosis induced by Bor if 
compared to MM cells in single culture. If Jagged ligands are knocked-
down, MM cells become again sensible to Bor, resulting in the loss of 
protection by BMSCs. These results indicate that Notch pathway has a role 
in BMSC-mediated Bor drug resistance. It is important to underline the fact 
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that Bor does not affect BMSCs viability: indeed BMSCs treated with 8 nM 
Bor do not show an increased apoptosis if compared to vehicle-treated 
cells (data not shown). 
 
2.2 Molecular and biological changes induced by Jagged-silenced 
MM cells in BMSCs 
 
2.2.1 Outcome on Notch signalling activity in BMSCs 
In this section, I will investigate the molecular mechanisms underlying the 
ability of MM-derived Jagged ligands to promote BMSCs pro-tumor 
behaviour. My hypothesis is that Jagged ligands my trigger a pro-tumor 
Notch signaling in BMSCs, To address this issue, I will measure the 
variation of Notch transcriptional activity analysing changes in the level of a 
acknowledged transcriptional target gene. 
U266 (A) or OPM2 (B) cells were silenced for 96h and co-cultured with 
murine NIH3T3 for last 48h. RNA was extracted and gene expression 
variation in NIH3T3 cells analysed by qRT-PCR. The analysis of the gene 
expression changes of the Notch target gene HES5 (HES5=Hairy enhance 
of split 5) indicated that Jagged ligands expressed on MM cells surface can 
trigger Notch pathway activation in BMSCs (figure 2.1.1): 
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Figure 2.2.1. Activation of Notch signalling in NIH3T3 cells by MM cell-
derived Jagged1/2; The expression of HES5 on NIH3T3 cells co-cultured 
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with HMCL-SCR or HMCL-JAG was analysed by qRT-PCR. GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase) gene was used as 
housekeeping gene; NIH3T3 cells=1. Fold changes were calculated by the 
2-ΔΔCt formula (for details see “Material and Methods” section), error bars 
show SD of three independent experiments. Statistical analysis performed 
by one tail t test; *=p<0.5. 
Indeed, as shown in figure 2.2.1, the HMCLs-SCR are able to activate Notch 
pathway in NIH3T3 cells. On the contrary, Jagged ligands were silenced in 
HMCLs, there was a significant reduction in HES5 gene expression levels 
demonstrating that MM cells were no longer able to activate Notch pathway 
in NIH3T3 cells.  
 
2.2.2 MM cell-derived Jagged positively regulates the ability of 
BMSCs to secrete growth factors by activating Notch signalling 
MM cells may induce BMSCs to secrete pro-survival factors fundamental 
for MM cells survival. We used the same co-cultures used for experiments 
in point 2.2.1 to investigate the outcome of silencing MM-derived 
Jagged1/2 on the ability of BMSCs to release IL-6 and SDF1α, two 
important cytokines in MM with important effects on drug resistance, tumor 
cells migration and osteoclasts maturation.  
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Figure 2.2.2 Jagged silencing in MM cells impairs the ability of co-cultured 
BMSCs to express the genes encoding for SDF1α and IL-6. U266 (A) or 
OPM2 (B) cells were silenced for 96h and co-culture with murine NIH3T3 
for last 48h. RNA was extracted and gene expression variation in NIH3T3 
cells analysed by qRT-PCR; GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) gene was used as housekeeping gene; NIH3T3 cells=1. 
Fold changes are calculated by the 2-ΔΔCt formula (for details see “Material 
and Methods” section), error bars show standard deviation of three 
independent experiments. Statistical analysis performed by one tail t test; 
*=p<0.5. 
SDF1a=Stromal derived factor 1a; IL-6=Interleukin-6. 
 
Results reported in figure 2.2.1, I demonstrate that HMCL-SCR can induce 
an upregulation of both SDF1A and IL-6 gene expression in NIH3T3 cell, 
on the contrary the absence of MM cell-derived  Jagged results in a 
significant reduction of the two genes expression, suggesting that both 
SDF1A and IL-6 are direct Notch target genes or are indirectly regulated by 
Notch signalling. 
The results obtained were confirmed at protein level by fluo-cytometric 
staining as shown in figure 2.2.2: 
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Figure 2.2.2 Jagged silencing in MM cells impairs the ability of co-cultured 
BMSCs to secrete growth factors. U266 (A) or OPM2 (B) cells were 
silenced for 96h and co-cultured with human HS5-GFP cells for further 48h. 
Histograms represent the level of intracellular SDF1α or IL-6 or isotype 
matching control (gray lines) analyzed by flow cytometry in HS5-GFP cells. 
Histograms are representative of 3 independent experiments with similar 
results. 
 
As shown in figure 2.2.2, BMSCs co-cultured with MM cells expressed 
increased SDF1α and IL-6 proteins if compared to BMSCs cultured alone; 
Jagged ligands inhibition reduces the secretion of SDF1α and IL-6 by 
BMSCs. 
 
2.2.3 Confirming the role of Notch1 signalling in promoting BMSC 
ability to secrete pro-tumorigenic factors. 
The results obtained suggested that HMCL-JAG induce BMSCs to secrete 
SDF1α and IL-6 by activating Notch signalling. To verify this hypothesis, I 
evaluated if Notch receptors activation in BMSCs could promote the 
secretion of SDF1α and IL-6.  
At this purpose, I specifically knocked down Notch1 receptor in HS5 cell 
due to its high levels of expression; HS5 cell line was treated twice, every 
48h, with 50 nM anti-Notch1 siRNA (HS5-N1) or scrambled control (HS5-
SCR).  
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Variations of SDF1α and IL-6 expression were assessed by flow cytometry 
(figure 2.1.3): 
 
 
Figure 2.2.3 Notch1 knock down decreases the expression of the anti-
apoptotic citokines SDF1α and IL-6, in BMSCs. Histograms display the 
levels of intracellular SDF1α and IL-6 in HS5 Scr or HS5 N1-KD, along with 
an isotype-matched control (gray line). Histograms are representative of 3 
independent experiments with similar results.  
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As reported in figure 2.1.3, specific Notch1 knock down is able to reduce 
the protein expression of SDF1α and IL-6 in HS5 treated cells. 
 
2.2.4 Effect of MM cell-derived Jagged1/2 on BMSC ability to 
support the anti-apoptotic background of MM cells 
In the previous section, I demonstrated that Notch signalling is crucial to 
induce BMSCs to support MM cells survival and increase their 
pharmacological resistance. Results obtained indicate that the molecular 
mechanism involved stems from the ability of MM cell-derived Jagged to 
trigger Notch signalling in BMSCs, that in turn induce the secretion of anti-
apoptotic factors, e.g. SDF1α and IL-6. In this paragraph, I will show the 
effect of inhibiting MM cells-derived Jagged in terms of gene expression 
and secretion of anti-apoptotic factors by BMSCs. 
To clarify the mechanism of rescue from apoptosis activated by “educated” 
BMSCs (stimulated by MM cells), I studied if it may be induced by variation 
in gene expression of anti-apoptotic proteins. At this purpose, I analyzed if 
HMCLs co-cultured with BMSCs expressed different levels of key factors 
such as, BCL-XL, BCL2, Survivin and ABCC1. Moreover, I verified if Jagged 
KD reduced their expression (figure 2.2.4). I took advantage of the two 
different co-culture systems reported in section 2.  
 
 
 
 
 
 
 
 
 
 
 62 
A. 
 
C
XC
R
4
B
C
L-
XL
B
C
L2
SU
R
VI
VI
N
A
B
C
C
10
5
10
12.0
17.5
Re
la
tiv
e 
Ex
pr
es
si
on
 (2
 -Δ
C
t ) 
U266-SCR + NIH3T3 U266-JAG + NIH3T3 
**
**
*
*
 
B. 
 
C
XC
R
4
B
C
L-
XL
B
C
L2
SU
R
VI
VI
N
A
B
C
C
10
1
2
3
4
5
6
Re
la
tiv
e 
Ex
pr
es
si
on
 (2
 - Δ
C
t ) 
OPM2-SCR + NIH3T3 OPM2-JAG + NIH3T3
*** **
***
** *
 
Figure 2.2.4 Gene expression of MM cells anti-apoptotic factors induced by 
BMSCs: outcome of Jagged1/2 silencing. The expression of anti-apoptotic 
genes were analysed by qRT-PCR. The expression in HMCL-JAG + NIH3T3 
cells was compared to that obtained in HMCL-SCR + NIH3T3 cells and 
normalized on HMLCs scr alone =1. GAPDH was used as housekeeping 
gene. Fold changes were calculated by the 2-ΔΔCt formula (for details see 
“Materials&Methods” section), error bars show SD of three independent 
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experiments. Statistical analysis performed by one tail t test; *=p<0.05; 
**=p<0.01; p<0.001. 
The results obtained demonstrated that HMCLs co-cultured with NIH3T3 
cells upregulated the expression of anti-apoptotic and pro-survival genes 
such as CXCR4, BCL-XL, BCL2, Survivin and ABCC1, by contrast in HMCL-
JAG anti-apoptotic genes were significantly downregulated. This result 
suggests that the release of pro-tumor factors by BMSCs induced by MM 
cell-derived Jagged1/2 may enhance tumor cell drug resistance by inducing 
the overexpression of anti-apoptotic genes. 
 
2.2.5 Effect of MM cell-derived Jagged1/2 on BMSC ability to 
increase the protein expression of anti-apoptotic factors in MM 
cells 
I validate previously obtained gene expression results analysing protein 
variations through a similar experiment, including only one variation: U266 
or OPM2 cells were silenced for Jagged1 and 2, co-cultured with HS5-GFP 
cells. Protein expression of BCL2, Survivin and ABCC1 was assessed by 
using specific primary antibodies and subsequent analysis by flow 
cytometry.  
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Figure 2.2.5 Protein expression of anti-apoptotic factors. U266 or OPM2 
were silenced for Jagged ligands and co-cultured with HS5-GFP. 
Histograms display the levels of CXCR4, BCL2, Survivin and ABCC1 
analyzed by flow cytometry in HMCL-SCR (green lines) or in HMCL-JAG (red 
lines), and an isotype-matched control (gray line). Histograms are 
representative of 3 experiments with similar results. 
CXCR4=C-X-C chemokine receptor type 4; BCL2=B-cell lymphoma 2; 
ABCC1=ATP-binding cassette subfamily C member 1. 
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As shown in figure 2.2.5, HMCLs-SCR co-cultured with HS5 human BMSCs 
were able to upregulate the protein expression of anti-apoptotic factors 
(BCL2, Survivin and ABCC1), oppositely, HMCLs-JAG express decreased 
levels of CXCR4, BCL2, Survivin and ABCC1 protein expression.  
On the whole, these results indicate that MM cells may educate BMSCs to 
promote pharmacological resistance by i) releasing pro-survival factors 
such as IL6 and SDF-1a and ii) stimulating the expression of anti-apoptotic 
factors in the same MM cell.  
The possibility that IL6 and SDF1a may be involved in the upregulation of 
the anti-apoptotic background of MM cell still need to be verified.  
Our results further indicate that MM cells-mediated “education” of BMSCs 
is carried out by triggering Notch activation through tumor-derived Jagged 
ligands. 
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3. STUDY ON THE OUTCOME OF CXCR4 SIGNALLING DOWNSTREAM 
NOTCH PATHWAY IN BMSC-MEDIATED BORTEZOMIB DRUG 
RESISTANCE 
The axis CXCR4-SDF-1α has a fundamental role in MM because it is 
involved in several process such as migration, immunosuppression, 
proliferation, drug resistance (104) and it is correlated with poor prognosis 
(105). A recent work carried out in MM cells, published by my research 
group has demonstrated that, the axis CXCR4-SDF-1α is transcriptionally 
controlled by Notch signalling and blocking Notch pathway activation with 
gamma secretase inhibitor XII (GSI-XII) inhibits the expression of both 
CXCR4 and SDF-1α at gene and protein levels (76). 
These evidences prompted me to verify if SDF-1α secreted by BMSCs 
might support tumor cell resistance to chemotherapeutic drugs. To address 
this issue, I verified if the inhibition of CXCR4 signalling by the antagonist, 
AMD3100, may increase HMCL drug sensibility.  
I tested my hypothesis on U266 cells co-cultured with HS5-GFP cells and 
treated with AMD3100 and 8 nM Bor. The percentage of apoptotic MM 
cells, analysed by flow cytometry, is shown in figure 3. 
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Figure 3. CXCR4 inhibition affects BMSC-mediated drug resistance in 
U266 cell. U266 cells were treated for 48h with 100 µM AMD3100, a 
CXCR4 inhibitor, co-cultured for 48h with HS5-GFP and treated for the last 
24h with 8 nM Bor or DMSO as vehicle. Apoptotic MM cells were measured 
by flow cytometry as Annexin-V+cells. Graph shows the mean values of 3 
independent experiments and error bars show SD. Statistical analysis was 
performed using ANOVA and Tukey’s post test: **= p<0.01. 
 
The results obtained demonstrated that, as expected, HS5 cells can 
significantly protect MM cells from drug-induced apoptosis; by contrast, if 
CXCR4 signaling is blocked by AMD3100 treatment, HS5 cells are no 
longer able to protect U266 cells from Bortezomib induced apoptosis, 
indicating that CXCR4-SDF-1α axis could mediate Bortezomib resistance 
in MM cells. 
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4. VALIDATION OF JAGGED LIGANDS ROLE IN BORTEZOMIB DRUG 
RESISTANCE OF PRIMARY MM CELLS. 
To confirm the biological relevance of Jagged mediated drug resistance in 
MM cells, ex vivo experiments were carried out on primary MM cells from 
patients. 
Primary MM cells and primary BMSCs were isolated from BM aspirates of 
MM patients. Primary CD138 positive MM cells were separated by 
immunomagnetic sorting, while BMSCs were isolated from the negative 
fraction adherent cells (see “Material&Methods” section for details). 
CD138+ cells were analysed by flow cytometry to verify the purity after 
positive selection, figure 4.1, and as expected, more than 90% of cells were 
positive for CD138 expression. 
 
Figure 4.1 Primary MM cells CD138 expression. After positive selection, 
primary MM cells were analysed for CD138 expression by flow cytometry. 
Histograms are representative of 3 experiments with similar results. 
 
Primary BMSCs were characterized either by optical imaging and by flow 
cytometry (figure 4.2): BMSCs are adherent big cells with a fibroblast-like 
shape which are positive for the expression of CD105 and CD90 and are 
negative for CD45, a pan-leucocyte marker, and for CD14, a monocyte 
marker.  
 
CD138 
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Figure 4.2 Morphological and flow cytometric characterization of primary 
BMSCs. Primary BMSCs were isolated from BM aspirates of MM patients. 
In panel A is shown morphological evaluation by optical imaging, picture 
was taken by Zeiss PrimoVERT Microscope; in panel B is shown flow 
cytometric characterization, the expression of surface proteins (red 
histograms), i.e. CD105, CD90, CD45 and CD14, and isotype-matched 
controls (blue histograms) were analysed by flow cytometry.  
 
Co-culture experiments of MM cells and BMSCs were performed in order to 
verify Jagged ligands ability to promote Bor drug resistance even in primary 
MM cells. The experiments were carried out only in co-culture system 
because primary MM cells could not survive without feeder primary 
BMSCs. 
Primary CD138+ MM cells from 10 MM patients were transduced with a 
lentiviral vector pLL3.7, carrying Jagged1 and 2 shRNA or Scr control o.n., 
then they were co-cultured for 72h with primary BMSCs previously stained 
with PKH26, a fluorescent dye that enables an easy detection of the two 
different populations by flow cytometry. Co-cultures were treated with 8nM 
Bor or the corresponding vehicle and the percentage of apoptotic MM cells 
was detected by flow cytometry, as shown in figure 4.3. 
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CD45 CD14 
B A 
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Figure 4.3 Jagged1 and 2 silencing affects the ability of BMSCs to promote 
drug resistance ex vivo. Apoptosis of primary MM CD138+ cells were 
assessed by flow cytometry by Annexin-V+ staining. Primary MM CD138+ 
cells were treated for 24 h with 8nM Bortezomib (10 patients). Apoptosis 
analysis was performed by on primary CD138+ MM cells; Statistical 
analysis was performed by using one-way ANOVA and Tukey’s post test: 
*=p<0.05; **= p<0.01; ***=p<0.001. 
 
The results obtained demonstrated that Jagged ligands knocked-down 
significantly increases the apoptosis of primary MM cells and their 
sensibility to pharmacological treatment with Bor, overcoming the 
protection of BMSCs.  
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5. EFFECT OF HYPOXIA ON NOTCH PATHWAY ACTIVATION 
Previous results, and evidences from this and other research groups 
outlined a key role of Notch signalling deregulation in determining MM cell 
aggressiveness and the ability to shape the microenvironment. This section 
of the work aims to investigate if the microenvironment surrounding the MM 
cell may induce the expression of Notch ligands or receptors or their 
activation.  
Genetic mutations at the basis of Notch pathway members deregulation in 
MM involve only 5% patients with a dysregulation of MAFB and c-MAF 
genes due to t(14;16)(q32;q23) and t(14;20)(q32;q11); Notch2 is a direct 
target of these transcription factors and, thereby results expressed at 
higher levels (74).  
The general sensibility of MM cells to Notch signaling inhibition and the 
general increase of Notch receptors and ligands during MM progression 
suggest that Notch signaling activation may be induced also by other 
aspects. The importance of the microenvironment in MM progression, 
prompted me to investigate its characteristics, moreover the evidences that 
the BM microenvironment is hypoxic (108) and hypoxia is reported to 
positively regulate Notch signaling activity (95) prompted me to evaluate  
the effect of BM hypoxia on Notch signalling activation in MM cells and the 
possible biological effects. 
 
5.1 Effect of hypoxia on the protein expression of Notch pathway 
members 
This preliminary work addressing the effect of hypoxia on HMCLs was 
carried out through an inhibitory approach performed by in vitro 
administration of a chemical compound, Cobalt Chloride (CoCl2). CoCl2 
mimics hypoxia thanks to its ability to inhibits HIF-1α degradation by 
blocking PDH enzyme, thus leading to the accumulation of HIF-1α; as a 
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result, HIF-1α can migrate into the nucleus and activate the transcription of 
hypoxia-responsive genes.  
As a first step I evaluated if CoCl2 treatment could activate HIF-1α in OPM2 
cell line.  
OPM2 cells were treated with 100 µM CoCl2 and analyzed at 2h, 6h, 12h, 
24h to determine by Western Blot analysis if variation in HIF-1α expression 
were associated to variation in Notch signaling members.  
 
 
5.1.1 Expression of HIF-1α by CoCl2 treatment in OPM2 cells.Western blot 
shows the expression level of HIF-1α in OPM2 cells after CoCl2 treatment 
for the reported time points. 100 mg of whole cell lysate were loaded in 
each lane. Actin was used as loading control. Results are representative of 
three independent experiments. 
HIF-1α=Hypoxia inducible factor-1α; C=Vehicle treated cells; T= CoCl2 
treated cells. 
 
Figure 5.1.1 confirms that CoCl2 induces an accumulation of HIF-1α in 
OPM2 cells after 2h of treatment and the expression of HIF-1α that 
increases in the subsequent timepoints in comparison to control cells.  
The next step was to evaluate if the activation of HIF-1α, by CoCl2 
treatment, is associated to the increased expression of Notch pathway 
members. At this purpose the analysis was initially focused on Jagged1 
C T C T C T C T 24h 2h 6h 12h -­‐110	  kDa HIF-­‐1α -­‐48	  kDa Actin 
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and the intracellular domain of Notch2 (ICN2) that are specifically 
overexpressed in OPM2 cell line and are relevant in MM progression.  
 
 
5.1.2 Expression of Notch pathway members after HIF-1α activation in 
OPM2 cells. OPM2 whole cells lysates were analyzed by western blot at 
the reported time points during treatment with CoCl2 for the expression of 
Jagged1 and ICN2. 100 mg of whole cell lysate were loaded in each lane. 
Actin was used as loading control.Results are representative of three 
independent experiments. 
C=Vehicle treated cells; T= CoCl2 treated cells. 
 
Results of western blot analysis reported in figure 5.1.2 show no 
modulation of Jagged1 and ICN2 protein.  
 
5.2 Effect of hypoxia on Notch transcriptional activity 
Although experiments in section 5.1 should be confirmed by a complete 
analysis of the effect of CoCl2 on all the Notch members, the obtained 
results suggested that it could not be played at a transcriptional level. 
Thereby, we investigated if CoCl2 might directly affect Notch receptor 
Jag1 Actin -­‐180	  kDa -­‐48	  kDa C T C T C T C T 
24h 2h 6h 12h 
ICN2 Actin -­‐83	  kDa -­‐48	  kDa 
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transcriptional activity as reported for HIF-1α in different cellular context 
(95).  
To address this issue we analyzed the outcome of CoCl2 on Notch 
transcriptional activity by a Notch responsive dual luciferase gene reporter 
assay. OPM2 cell line was transfected for 48h with a reporter plasmid 
carrying Firefly luciferase controlled by a Notch-responsive promoter 
named 13XCSL and a second plasmid constitutively expressing Renilla 
luciferase for normalization of transfection efficiency (for details see 
“Materials & Methods”). Transfected cells were treated with100 µM CoCl2 
for last 24h and then luciferase activities were sequentially assessed by 
measuring their luminescence (figure 5.2.1): 
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5.2.1 CoCl2 treatment can modulate Notch transcriptional activity in OPM2 
cell line. OPM2 cells were transfected for 48h with a Notch reporter and 
treated for last 24h with 100 µM CoCl2 or with vehicle (Ctrl). Experiments 
were normalized using Renilla firefly; graph shows the mean values of 3 
independent experiments and error bars show SD. Statistical analysis was 
performed using one tail t test: p<0.05. 
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The results of dual luciferase assay shown in figure 5.2.1 demonstrate that 
CoCl2 treatment can induce a 5-fold increase of Notch transcriptional 
activity. 
To confirm and better characterize the molecular mechanism by which HIF-
1α accumulation enhances Notch transcriptional activity, I used a different 
in vitro model characterized by a higher transfection efficiency, the HEK293 
cell line.  
HEK293 cells were transiently transfected with the 13XCSL reporter and a 
plasmid that constitutively express high levels of ICN1 or ICN2, the most 
relevant isoforms in MM (see Materials and Methods for plasmids details); 
HEK293 cells were treated with CoCl2 as previously reported and luciferase 
activity triggered by ICN1 or ICN2 was measured by dual luciferase assay 
(figure 5.2.2). 
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5.2.2 HIF-1α activation positively modulates ICN1 and ICN2 transcriptional 
activity in HEK293 cells. HEK293 cell line were transfected for 48h with 
13XCSL plasmid and either plasmid expressing ICN1 or ICN2 or empty 
plasmid (Mock) and treated for last 24h with 100 µM CoCl2 or with vehicle 
(Ctrl). Transfection efficiency was normalized using Renilla firefly; graph 
shows the mean values of 3 independent experiments and error bars show 
SD. Statistical analysis was performed using one tail t test and comparing 
for each set cells treated with vehicle to CoCl2 treated cells: p<0.05. 
 
Results shown in figure 5.2.2 confirm that CoCl2 treatment increases the 
luciferase activity triggered by the endogenous Notch receptors in HEK293 
cells and indicate that CoCl2 positively regulates ICN1 and ICN2 
transcriptional  activity.  
This result indicates that a hypoxic microenvironment may activate Notch 
signalling by a positive regulation of ICN1 and ICNs activity operated by 
HIF-1a and suggest that this may occur also in MM cells.  
 77 
 
5.3 Study on the role of Notch pathway as a downstream mediator 
of HIF-1α  supportive effect on MM stem cell population 
Cancer stem cells (CSC) have been described as a subpopulation 
characterized by high level of rdug resistance, ability to give raise to the 
bulk population and the ability to metastatize recreating further tumors 
masses in distant sites (109). CSCs have been found in different cancer 
types (97, 110). 
Matsui et al. described the MM-SCs as a population characterized by a 
CD138- phenotype, clonogenic ability and intrinsic drug resistance (101, 
102).  
From literature it is known that both hypoxia and Notch pathway can 
sustain and maintain the stem cell niche (111, 112). This induced me to 
evaluate if hypoxia positively regulates the amplification of MM-SCs and 
this effect required Notch signalling activation. To address this issue I 
induced hypoxia with CoCl2, analyzed the outcome on MM-SC population 
size (expected an increase), and verified if it could be reversed by inhibiting 
Notch signaling.  
I choose, as a model, the MM cell line H929 due to a higher percentage of 
CD138- MM-SCs in comparison to other HMCLs. To mimic a hypoxic-like 
condition, H929 cell line was treated for 96h 20 µM CoCl2 and to block 
Notch signalling cells were treated with 50 µM DAPT, a γ-secretase 
inhibitor, or a combination of the two drugs. At the end of the experiment, 
cells were analysed by flow cytometry to detect variations in CD138- 
population (figure 5.3).  
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Figure 5.3 HIF-1α activation expands MM-SC subpopulation in H929 cells. 
Variation of CD138- population was assessed by flow cytometry staining of 
CD138. Graph shows the mean values of 3 independent experiments and 
error bars show SD. Statistical analysis was performed by two-way ANOVA 
and Holm-Sidak post’s test: *=p<0.05; **=p<0.01. 
 
The results shown in figure 5.3 demonstrate that CoCl2 treatment increases 
CD138- cell population, while DAPT treatment significantly decreases it, as 
expected. The double treatment demonstrates that the positive effect of 
HIF-1α activation on CD138- population requires active Notch signalling, 
indeed the effect of CoCl2 is significantly dampened by DAPT. 
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DISCUSSION&CONCLUSION 
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MM represents 10% of all haematological malignancies. Despite new drugs 
development, it is still incurable with an overall survival of 8 years at 
diagnosis. Neoplastic cells accumulate within the BM microenvironment, 
where they interact with different cell types, among which the BMSCs that 
support cancer cell growth and mediate drug resistance. MM cells display 
an intrinsic resistance to a specific drug after treatment and this process is 
known as “acquired drug resistance”, while they can become drug resistant 
also stimulated by interactions with other different cell types, i.e. BMSCs or 
OCLs. In this process, cell interactions can trigger the secretion of 
cytokines which are able to mediate MM cells drug resistance (85). 
Notch receptors are members of a highly conserved family during 
evolution; the family is composed by 4 receptor isoforms, Notch1-4, and 
two ligands families, Jagged (Jagged1-2) and Delta (Dll1-3-4) ligands. 
Upon receptor-ligand interaction, two proteolitic cleavages enable the 
release of the intracellular form of Notch into the nucleus, where it is able to 
activate the transcription of the target genes. Notch has a role in different 
cellular process, i.e. proliferation, apoptosis, cellular differentiation, adult 
tissue homeostasis and maintenance of stem cells. Because of its 
relevance, Notch receptor or ligands mutations or deregulation are often 
associated to cancer onset and progression (3). 
In MM, Notch deregulation can be found at both receptors and ligands level 
and the deregulation positively correlates with disease stage and 
progression (41, 75, 113-116). MM cell express both Notch receptors and 
ligands, thus inducing either homotypic activation of Notch pathway in other 
MM cells, or heterotypic interactions with the other cells within the BM 
microenvironment. According to this, Notch signalling is able to affect the 
biology of MM cell and its pathological interaction with other cells, for 
example BMSCs. Previous published work from Chiaramonte’s group and 
others teams demonstrated how Notch inhibition, by GSIs treatment, 
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results in increased apoptosis, decreased cell proliferation (6, 76, 114, 117) 
and increased drug sensitivity of MM cells (106, 118). 
Besides genetic alterations that cause Notch pathway hyperactivation, 
there are other factors that can modulate Notch signalling activity among 
which hypoxia. The BM environment is, by definition, hypoxic (119); HIF-1α 
is the master regulator of hypoxic response and it is a transcription factor 
that induces the expression of genes involved in different processes such 
as angiogenesis, metabolism shift towards anaerobic glycolysis, cell cycle 
arrest and maintenance of stem cell population (88). Recent evidences 
indicate that Notch pathway and hypoxia pathway physically interact: 
Gustaffson and colleagues demonstrated that HIF-1α and Notch interact 
together; the mechanism is still unclear but different mechanisms have 
been proposed based on as many evidences: i) HIF-1α can positively 
regulates Notch pathway members; ii) HIF-1α has been proposed to bind 
the ICN and stabilize it preventing ICN degradation via proteasome 
machinery; iii) HIF-1 α induces Notch pathway members by binding 
hypoxia responsive elements (HRE) in Notch gene promoter (95). 
Hypoxic condition and Notch signalling synergistically cooperate to sustain 
the cancer stem cells (CSCs) population that is intrinsically drug resistant 
and responsible for tumour relapse in patients (70); Matsui and colleagues 
first described MM-stem cells (MM-SCs) as a population characterized by a 
CD138- phenotype, clonogenic ability, drug resistance and able to generate 
a primary tumour mass if injected in mice (101, 102). 
The aim of my work is to evaluate the role of Notch pathway in mediating 
intrinsic and BMSC-mediated drug resistance in MM cells; furthermore I 
have studied the role of hypoxia on Notch signalling to better characterize 
the mechanism by which they interact and the effect on MM-SCs. 
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In the first part of my thesis, I focused my attention on the effect of Jagged 
silencing on MM cell biology in terms of drug resistance. 
Since MM cells overexpress Jagged ligands, I decided to choose a Jagged-
directed approach to specifically inhibit Notch pathway activation. At this 
purpose, I treated MM cells with two specific siRNAs targeting Jagged1 and 
2 because (75, 116). MM cell lines, OPM2 and U266, were treated with 
anti-Jagged1/2 siRNAs (HMCL-JAG) or scrambled control (HMCL-SCR) and 
the effect of silencing was assessed by qRT-PCR on Notch pathway 
activation by measuring gene expression of Jagged1, Jagged2 and of two 
Notch-target genes, HES1 and HES6. My results show that, after silencing, 
Jagged ligands expression was impaired and the expression of two Notch 
target genes, HES1 and HES6 (76, 106), was inhibited demonstrating that 
Notch pathway was knocked down. 
The next step was to evaluate the biological effect of Jagged silencing on 
intrinsic Bortezomib drug resistance. HMCL-SCR or HMCL-JAG were treated 
with Bortezomib and apoptosis measured; the results indicate that drugs 
are able to induce apoptosis in HMCL-SCR, and if Notch pathway is silenced, 
MM cells are more sensitive to Bortezomib, confirming results obtained by 
Nefedova and colleagues and Chen and colleagues who demonstrated that 
MM cell are more sensitive to drugs if Notch pathway is blocked by GSI 
treatment (106, 118). 
To better characterize the mechanism by which Notch pathway mediates 
MM cell drug resistance, I studied the expression of anti-apoptotic proteins, 
both at gene and protein level, such as CXCR4 (CXCR4=C-X-C chemokine 
receptor type 4), BCLXL (BCL-XL=B-cell lymphoma-extra large), BCL2 
(BCL2=B-cell lymphoma 2) and ABCC1 (ABCC1=ATP-binding cassette 
subfamily C member 1) that are known Notch transcriptional target genes 
in different cellular context. Regarding CXCR4, Chiaramonte’s group has 
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previously demonstrated that it is regulated by Notch and regulates 
apoptosis, migration, BM homing and proliferation of MM cells (76); ABCC1 
encodes for a transmembrane efflux pump which transports out of the cells 
many chemical compounds and therefore has a role in drug resistance 
(107). My results show that Jagged ligands silencing decreases the 
expression of anti-apoptotic proteins at both gene and expression level. 
Taken together these findings are consistent with a previously published 
work in which the authors demonstrated that if paclitaxel-resistant ovarian 
cancer cells were treated with GSI, they become more sensitive to drugs 
and show a reduction in anti-apoptotic proteins expression background 
(120). 
The results obtained in the first part of my thesis concern “intrinsic” drug 
resistance, but MM cell localize within the bone marrow where they interact 
either with other MM cells (homotypic interaction) or other types of cell 
(heterotypic interaction), e.g. monocytes, osteoclasts and BMSCs. This 
communication among cells can be mediated by direct contact or soluble 
factors.  Chiaramonte’s group has demonstrated that MM-associated 
osteoclastogenesis is due to either the release of soluble RANKL or the 
direct contact of MM cells with osteoclasts progenitors resulting in Notch 
signalling activation (78). 
BMSCs mediate MM cells survival and drug resistance, for this reason in 
the second section of my thesis, I analysed the role of Notch pathway in the 
interaction between MM cells and BMSCs and the effect on BMSC-
mediated drug resistance. 
The first step was to analyse the outcome of Jagged silencing on drug 
resistance induced by MM cell-BMSCs interaction. MM cells were silenced 
for Jagged expression and co-cultured with HS5, a human stromal cell line 
used to mimic BMSCs, and treated with drugs used in MM therapy. The 
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results obtained show that BMSCs are able to protect MM cell from drug-
induced apoptosis; but BMSCs are no longer able to protect MM cells 
silenced for Jagged ligands, suggesting that Notch pathway activated by 
MM-derived Jagged has a role in BMSC-mediated drug resistance. 
To clarify the mechanism by which BMSCs are able to mediate MM cells 
drug resistance, I analysed the outcome BMSCs gene and protein 
expression upon their interaction with MM cells carrying high or low levels 
of Jagged ligands. 
I first verified that variations in the levels of Jagged expressed by MM cells 
upon silencing resulted in a corresponding change in Notch signalling 
activation in co-cultured BMSCs, assessed as variations in the expression 
in the Notch target genes belonging to the HES family of genes. 
I further verified that Notch activation was associated to the increased 
release of important cytokines, i.e. IL-6 and SDF-1α. It is known that 
BMSCs have a supportive role for MM cells in terms of secretion of 
cytokines or growth factors among which IL-6 and SDF-1α. IL-6 and SDF-
1α are important for MM cells because they mediate different processes 
crucial for MM proliferation, drug resistance, BM homing and osteoclasts 
maturation (76). 
To elucidate how Jagged silenced-MM cells can modulate the release of IL-
6 and SDF-1α by BMSCs, HMCL-SCR or HMCL-JAG were co-cultured with 
NIH3T3 or HS5 cell line to mimic BMSCs and I evaluate the expression of 
IL-6 and SDF-1α at both genic and protein level by BMSCs. The results 
showed that HMCL-SCR are able to upregulate the expression of the two 
cytokines while if BMSCs are co-cultured with HMCL-JAG there is a 
decrease in the expression of IL-6 and SDF-1α, demonstrating how their 
expression is regulated by Notch pathway. These results are in accordance 
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of previous works published by Chiaramonte’s research group in which 
they demonstrate that both IL-6 and SDF-1α are positively regulated by 
Notch signalling (76) (121). 
To confirm the involvement of Notch pathway in mediating cytokines 
release (IL-6 and SDF-1α) by BMSCs, I specifically knock-down Notch1 
receptor expression by using specific siRNA in HS5 cell line. The results 
obtained demonstrate that if expression of Notch1 is blocked, the protein 
expression of IL-6 and SDF-1α is reduced thus confirming that Notch 
pathway needs to be active to induce the secretion of IL-6 and SDF-1α by 
HS5 cells. 
To clarify the molecular outcome of BMSC-induced drug resistance in MM 
cells, I investigated changes in the anti-apoptotic background of MM cells. 
In particular, I analyzed the expression of anti-apoptotic proteins, BCLXL, 
BCL2 and ABCC1 involved in MM cells drug resistance. HMCL-SCR or 
HMCL-JAG were co-cultured with HS5 cells and variations of anti-apoptotic 
factors at gene or protein level were assessed: results show that, upon co-
culturing, the expression of anti-apoptotic factors is significantly increased 
in HMCL-SCR if compared to HMCL-JAG; these findings are supported by the 
fact that MM cell-derived Jagged ligands are able to activate Notch 
pathway in HS5 cells, that in turn induces the upregulation of BCLXL, BCL2 
and ABCC1 in MM cells; furthermore, the activaction of Notch pathway in 
BMSCs induce the release of soluble factors which are able to promote the 
expression of BCLXL, BCL2 and ABCC1 as well in MM cells, thus 
demonstrating that MM-derived Jagged ligands are necessary to induce the 
expression of anti-apoptotic proteins.  
These results, taken together, indicate that MM cells are able to “shape” 
BMSCs thanks to the expression of Jagged ligands, in turn educated 
BMSCs secrete pro-tumor soluble factors such as IL-6 and SDF-1α and to 
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support an increased anti-apoptotic background in MM cells thus mediating 
drug resistance. 
As mentioned above, the chemokinic axis CXCR4-SDF-1α has a 
fundamental role in MM cell biology because it is involved in different 
biological processes like proliferation, migration (76), drug resistance (104) 
and correlates with poor prognosis (105). Furthermore, an article published 
by Dr. Chiaramonte’s lab demonstrates that the axis CXCR4-SDF-1α is 
controlled at transcriptional level by Notch, and blocking Notch pathway 
activation by GSI-XII treatment results in reduced expression of both 
CXCR4 and its ligand SDF-1α (76). 
The next step in my thesis was to test if SDF-1α secreted by BMSCs could 
have a role in mediating MM cells resistance to drugs: U266 cell line in 
single culture or in co-culture with HS5 cell line was treated with AMD3100, 
a compound that antagonize CXCR4 receptor, and with commonly used 
drugs such as Bortezomib and Melphalan. The results indicate that HS5 
cells can protect MM cells from drug-induced apoptosis but if CXCR4 is 
blocked by AMD3100, HS5 cells loose their protective effect and U266 
significantly increses sensibility to Bortezomib; the results are no significant 
for Melphalan-treated cells indicating that CXCR4 may have a role in 
Bortezomib resistance. 
These findings are in accordance to previous work published in literature by 
Waldschmidt et al. in which demonstrates that MM cells co-cultured with 
stromal cells and treated with AMD3100 are more sensitive to Bortezomib 
and Pomalidomide; the authors also hypothesize that CXCR4 is 
responsible for adhesion-mediated drug resistance (122). 
To confirm the biological relevance of Jagged ligands induced drug 
resistance, I validate the results in ex vivo experiments on primary CD138+ 
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MM cells. Primary CD138+ MM cells and primary BMSCs were isolated 
from bone marrow aspirates of MM patients at the onset of the disease. 
Specific Jagged ligands silencing was obtained in primary CD138+ MM 
cells by lentiviral infection and the results demonstrated that Jagged knock-
down increase the sensibility of primary CD138+ MM cells to Bortezomib by 
reducing the protective effect of primary BMSCs. 
The last part of my thesis investigated if bone marrow microenvironment 
could trigger the expression of Notch receptor or ligands and activate the 
pathway. As reported above, genetic alteration are at the basis of Notch 
pathway deregulation: for example, 5% patients, which carry 
t(14;16)(q32;q23) and t(14;20)(q32;q11), show a dysregulation in MAFB 
and c-MAF genes that cause Notch2 overexpression (74). Evidences 
demonstrate that Notch pathway members expression increase during MM 
progression thus suggesting that there are other factors that influence 
Notch receptors or ligands expression: the bone marrow in an hypoxic 
microenvironment and, since Gustaffsson et al. demonstrate that HIF-1α 
positively regulates Notch signalling (95), I decide to evaluate the role of 
hypoxia on Notch pathway on MM cell biology. 
To mimic hypoxia, I treated OPM2 cells with CoCl2, which is a chemical 
compound that cause the accumulation of HIF-1α and, after CoCl2 
treatment there is an accumulation of HIF-1α at every timepoint. The next 
step was to evaluate if the accumulation of HIF-1α correspond to an 
increased expression of two Notch pathway members at protein level: 
Jagged1 and the intracellular domain of Notch2 (ICN2); my analysis was 
initially focused on Jagged1 and ICN2 because they are highly expressed 
by OPM2 cell line and the results show that there is no modulation in the 
protein expression of both Jagged1 and ICN2 indicating that HIF-1α cannot 
modulate the transcription of Notch pathway members. To better elucidate 
the mechanism by which HIF-1α modulates Notch pathway activity, I 
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wondered if hypoxia can affect the transcriptional activity of Notch 
intracellular domain (ICN). To verify my hypothesis, thanks to a reporter 
system, I demonstrate that CoCl2 is able to increase the transcriptional 
activity of Notch intracellular domain in OPM2 cell line; to better dissect the 
mechanism and to determine if a specific Notch isoforms is involved in this 
process, I set up an in vitro reporter system model characterized by high 
transfection efficiency; I forced the expression of ICN1 and ICN2: I chose 
these two Notch isoforms because are the most relevant for MM disease 
(41). The results indicate that CoCl2 treatment enhances the transcriptional 
activity of both Notch isoforms. These data are in accordance with a 
previously published work in which the authors proposed a mechanism by 
which HIF-1α modulates Notch pathway activity: basing on the obtained 
results, the authors hypothesisez that HIF-1α binds the ICN thus protecting 
it from degradation and increasing its half-life and transcriptional activity 
(95). 
From literature it is known that hypoxia and Notch signalling cooperate to 
sustain the CSC niche: CSC are intrinsically drug resistance and display 
clonogenic ability; Matsui and colleagues first described MM-SCs and 
demonstrate that they have CD138- phenotype, are drug resistant, have 
clonogenic potential and if injected are able to generate a tumour mass 
(101, 102). All these evidences, prompted me to analyse the effect of Notch 
pathway and hypoxia on MM-SC population. H929 cell line was choosen 
due to their higher reservoir of CD138- MM-SCs if compared to other MM 
cell lines; hypoxia was mimicked with CoCl2 treatment and Notch signalling 
was blocked after treatment DAPT, a γ-secretase inhibitor. 
The results showed that, as expected, HIF-1α accumulation increased the 
CD138- population and oppositely blocking Notch pathway significantly 
decrease it; while the double treatment demonstrated that the effect of 
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hypoxia on CD138- MM-SCs population requires an active Notch pathway 
as demonstrated by DAPT ability to weaken CoCl2 treatment. 
Further experiments are needed to better characterize the mechanism by 
which hypoxia and Notch pathway interacts. 
The future directions of this work include the validation in vivo in Zebrafish 
animal model. MM cells can be injected in Zebrafish either by injection in 
the perivitelline space (123) or by intracardiac injection (124). Sacco et al. 
demonstrate that MM cells xenografts migrate in the caudal haematopoietic 
tissue (CHT) which mimic mammalian BM function supporting MM cells 
growth and engraftment (104). I will inject Zebrafish with MM cells that 
conditionally express anti-Jagged1 and 2 siRNAs upon doxacycline 
treatment; fishes with xenografts will be treated with drugs and apoptosis 
rate of MM cells was assessed. 
The results obtained in this thesis provide the rational for considering 
Jagged ligand as a new therapeutic target to overcame, on one hand MM-
associated drug resistance and, on the other hand, gut toxicities due to GSI 
treatment (125) (126). 
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MATERIALS & METHODS 
 
 
 
 
 
 
 
 
 
 
 
1. CELL CULTURES 
1.1 SINGLE CULTURES 
Multiple myeloma cell lines (HMCL) used were: 
- OPM2: established in 1982 from the peripheral blood of a 56-year-
old woman with multiple myeloma (IgG lambda) in leukemic phase 
 91 
(relapse, terminal); cells negative for CD3, CD10, CD19, CD80 and 
CD20, cells positive for CD138. They grow in suspension. 
- U266: established in 1968 from the peripheral blood of a 53-year-
old man with IgE- secreting myeloma (refractory, terminal); cells 
were described to produce IgE lambda; cells negative for CD3, 
CD10, CD19 and CD20 and positive for CD138. They grow partially 
adherent.  
- NCI-H929: established from the pleural effusion of a 62-year-old 
woman with myeloma (IgA kappa) at relapse; cells synthesize high 
amounts of immunoglobulin; cells are neagtive for HLA DR and 
markers of early B cell development; cells are positive for CD38. 
They grow in suspension. 
 
All MM cell lines were  maintained  in  75  cm2  flask  in  RPMI  1640  
medium (Sigma-Aldrich  Co.,  St  Louis,  MO),  supplemented  with  10%  
(v/v)  FBS (Gibco,   Rockville,   MD),   2   mM   L-glutamine   (Invitrogen 
Corporation Carlsbad, CA, USA), 100  U/ml  penicillin and 100 µg/ml  
streptomycin. The serum was de-complemented for 30’ at 56°C before use. 
Cells were cultured in 5% CO2 at 37°C, maintaining the optimum 
concentration at 3x105 cells/ml with complete change of medium every two 
days. 
 
The fibroblast cell line used as mimetic of bone marrow stromal cell 
(BMSC) was: 
- NIH3T3: cell line of  mouse  embryonic  fibroblasts  isolated  in  
1962  at  the New  York  University School of Medicine  Department  
of  Pathology.  They grow adherent. 
- HS5-pGIPZ: Stable cell line derived from HS5 cells that were stably 
transfected with the lentivirale vector pGIPZ to express green 
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fluorescent protein (GFP). Cells were maintained in culture adding 1 
µg/mL puromycin for selection. 
 
The cell line used as a model for luciferase assay was: 
- HEK293: cells were isolated from an human aborted fetus in 1973. 
 
Both BMSCs or HEK293 cell lines were maintained in 10 cm2 plate dishes, 
in DMEM medium  (Sigma-Aldrich Co., St Louis, MO, USA), supplemented 
with 10% (v/v) FBS (Gibco, Rockville, MD, USA), 2 mM L-glutamine 
(Invitrogen Corporation Carlsbad, CA, USA), 100 U/ml penicillin   and 100 
µg/ml streptomycin. The serum was de-complemented for 30’ at 56°C 
before use. Cells were cultured in 5% CO2 at 37°C, with complete change 
of medium every two days. 
 
1.2 CO-CULTURE SYSTEMS 
NIH3T3 or HS5-pGIPZ were plated in 24-well plate at different 
concentration: 1,5x105 cell/mL (OPM2) or 7,5x104 cell/mL (U266). After 24h 
MM cell line, OPM2 or U266, were plated on BMSCs monolayer at 
concentration of 3x105 cell/mL. Co-cultures were maintained in RPMI full 
for 48h and analysed by flow cytometry or for gene expression analysis. 
2. TREATMENTS 
2.1 NOTCH PATHWAY INHIBITION BY DAPT 
Notch pathway inhibition was obtained by DAPT (N-[N-(3,5-
difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester, Sigma-Aldrich), 
also known as GSI-IX, that is a γ-secretase inhibitor. It is dissolved in 
DMSO. The cells were treated with 50 µM DAPT and controls with the 
same amount of DMSO. 
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Figure 2.1 DAPT molecular structure. 
 
2.2 HIF-1α ACTIVATION BY CoCl2 TREATMENT 
CoCl2 (Cobalt chloride) is a chemical compound that blocks the 
degradation of HIF-1α by inhibiting PDH (Proline hydroxylase) enzyme thus 
causing an accumulation of active HIF-1α in the cytoplasm. It is dissolved 
in water. Cells were treated with 100 µM or 20 µM CoCl2 and controls were 
treated with the same amount of water. 
 
2.3 DRUG 
To test MM cells Bortezomib drug resistance, cells were treated with 8 nM 
Bortezomib (Sigma-Aldrich) for 24h. Controls were treated with the same 
amount of DMSO. 
 
 
Figure 2.3.1 Bortezomib molecular structure. 
 
 
 
 94 
3. GENE EXPRESSION ANALYSIS 
3.1 RNA EXTRACTION 
Total RNA was extracted by TRIzoL® reagent (Sigma-Aldrich). Protocol is 
optimized for 106 cells: 
• Add 1 mL of TRIzol® Reagent. 
• Lyse cells in sample by vortexing. 
• Incubate the homogenized sample for 5 minutes at room 
temperature 
• Add 0.2 mL of chloroform and vortex sample for 10 seconds. 
• Incubate for 15 minutes at room temperature. 
• Centrifuge the sample at 12000g for 15 minutes at 4°C. Note: The 
mixture separates into a lower red phenol-chloroform phase, an 
interphase, and a colorless upper aqueous phase. RNA remains 
exclusively in the aqueous phase. 
• Remove the aqueous phase of the sample into a new tube. 
• Add 0.5 mL of 100% isopropanol to the aqueous phase, and vortex 
sample for 10 seconds. 
• Incubate at room temperature for 10 minutes. 
• Centrifuge at 12000g for 10 minutes at 4°C. 
• Remove the supernatant from the tube, leaving only the RNA pellet. 
• Wash the pellet, with 75% ethanol. 
• Centrifuge the tube at 7500g for 5 minutes at 4°C and discard the 
supernatant. 
• Air dry the RNA pellet for 5–10 minutes at room temperature. 
• Re-suspend the RNA pellet in RNase-free water. 
• Incubate at room temperature for 10–15 minutes. 
• Proceed to downstream application, or store at –70°C. 
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3.2 RNA QUANTIFICATION 
RNA was quantified by Nanodrop (ThermoFisher) using 1 µl of RNA and 
following manufacture’s instruction. 
 
3.3 REVERSE TRANSCRIPTION 
cDNA was obtained by reverse transcription with RevertAid M-MuLV 
Reverse Transcriptase (ThermoFisher). 
The reaction was settled as follow: 
• 1µg RNA 
• 1µl of Random primers (25 0ng/µl) 
• H2O DEPC up to 10µl 
• Sample was heated at 65°C for 5’. 
The mix was prepared as follow: 
• 4µl of 5x RT Buffer 
• 4µl dNTPs 10 mM (2.5 mM each) 
• 1µl of RevertAid M-MuLV Reverse Transcriptase (200 U/µl) 
• 1µl of H2O DEPC 
The mix was added to the reaction composed by RNA and Random 
primers and incubated at 42°C for 1 hour. Samples were stored at -20°C or 
used for downstream application. 
 
3.4 QUANTITATIVE REAL-TIME PCR 
Quantitative PCR is an amplification technique that allow for simultaneous 
quantification of PCR products. It is based on the presence in the reaction 
mix of a fluorescent reporter 
(SYBR Green) that is able to intercalate in dsDNA and to reveal the 
presence of PCR amplicons; fluorescence signal is directly proportional to 
the specific amplification products.  
Gene target expression was obtained using the ΔCt method; GAPDH was 
used as housekeeping gene. Differences in gene expression between two 
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different conditions, e.g. treated vs control, were determined using the 
ΔΔCt method. In detail, was applied the following formula 2−ΔΔCt: 
- Ct (cycle threshold): represents the number of cycles at which the 
detector started to reveal the presence of PCR products. 
- ΔCt: represents the difference between the Ct of the target gene and the 
Ct of the housekeeping gene. 
- ΔΔCt: represents the difference between the ΔCt of the treated sample 
and the ΔCt of the control sample. 
Quantitative PCR (qRT-PCR) reactions were carried out on a Step-One 
Plus PCR system (Applied Biosystems, Life Technologies Italia, Italy) using 
the Maxima SYBR Green/ROX qPCR Master Mix (2X) (ThermoFisher 
Scientific). 
The reaction mix for a 96 well plate is the following (final volume of 15 µl): 
• 7,5µl Maxima SYBR Green Master Mix (2X) 
• 2 µl Primer Mix (final concentration 0,45 µM) 
• 2 µl cDNA 5ng/µl (10 ng total) 
• 3,5 µl H2O RNasi-free 
 
The following program was used: 
• Hot start activation: 95°C for 10’ 
• Denaturation 
• Annealing 
• Dissociation 
 
 
 
 
40 cycles 95°C for 15” 
60°C for 60” 
95°C for 15” 
60°C for 15” 
85°C for 15” 
 97 
 
Table 3.4 qRT-PCR primers sequence. 
 
4. RNA INTERFERENCE 
To specifically block Notch pathway, OPM2 and U266 cell lines were 
treated with two specific anti-Jagged1 and 2 siRNAs or with scrambled 
control in order to verify that any gene expression change occurs upon 
siRNAs delivery. 
Cells treated with fluorescent sdRNA “BLOCK-IT” (Life Technologies Italia, 
Milan, Italy) were used as positive control. 
Stealth Select RNAiTM siRNA system (Life Technologies Italia, Milan, Italy) 
was used according to the manufacturer’s instructions. The protocol 
includes the following steps: 
 
 
RT-qPCR 
primer 
 
 
 
Forward primer 5’-3’ 
 
 
 
Reverse primer 5’-3’ 
hGAPDH ACAGTCAGCCGCATCTTCTT AATGGAGGGGTCATTGATGG 
hJAGGED1 TTCGCCTGGCCGAGGTCCTAT GCCCGTGTTCTGCTTCAGCGT 
hJAGGED2 CCGGCCCCGCAACGACTTTT CCTCCCTTGCCAGCCGTAGC 
hHES1 GATGCTCTGAAGAAAGATAGC GTGCGCACCTCGGTATTAAC 
hHES6 ATGAGGACGGCTGGGAGA ACCGTCAGCTCCAGCACTT 
hCXCR4 GGCCTTATCCTGCCTGGTAT TCGATGCTGATCCCAATGTA 
hBCL-XL CGTAGACAAGGAGATGCAGGTA CTGCTGCATTGTTCCCATAGAG 
hBCL2 GTCATGTGTGTGGAGAGCGT GCCGTACAGTTCCACAAGG 
hSURVIVIN AGCCAGATGACGACCCCAT CTTGGCTCTTTCTCTGTCCA 
hABCC1 TAATCCCTGCCCAGAGTCCA ACTTGTTCGGACGTGTCCTC 
mGAPDH TTGGCCGTATTGGGCGCCTG CACCCTTCAAGTGGGCCCCG 
mHES5 GGCTCACCCCAGCCCGTAGA TCGTGCCCACATGCACCCAC 
mSDF-1α CAGCTCTGCAGCCTCCGGC AAGAACCGGCAGGGGCATCG 
mIL-6 TGAACAACGATGATGCACTTGCAGA TCTCTGAAGGACTCTGGCTTTGTCT 
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- OPM2 or U266 cells were plated at 3x105/ml in medium without 
antibiotics in 24-well plate in 500 µl final volume.   
- siRNAs (25 nM anti-Jagged1 + 25 nM anti-Jagged2 / or 50 nM 
scrambled  siRNA/ or 50 nM fluorescent dsRNA ) were diluted in 50 
µl of Opti-MEM medium (Invitrogen, Life Technologies Italia, Milan, 
Italy) without serum and antibiotics.   
- 1µl of RNAi-MAX lipofectamine transfecting reagent (Invitrogen, Life 
Technologies Italia, Milan, Italy) was diluted in 50 µl of Opti-MEM 
medium without serum and antibiotics.   
- The two solutions (siRNA/lipofectamine) were mixed and incubated 
for 20’ at room temperature; 100 µl of lipofectamine/siRNA mix was 
added to the cells. 
- Every 48h cells were diluted 1:1 with medium antibiotics-free and 
treated again with Jag1/Jag2 siRNA up to 96h. 
To confirm that the transfection occurred successfully, the percentage of 
BLOCK-IT positive cells were checked trough flow cytometry analysis at 
each time point. 10000 cells were acquire with BD FACSVerse and 
analysed with FACSuite Software (BD, San Jose, CA). 
To test the specific Jagged1 and Jagged2 knock-down, silenced MM cells 
were analysed by qRT-PCR and compared to scrambled control. 
5. FLOW CYTOMETRY 
To carry out flow cytometry experiments, BD FACSVerse was used and 
experiments analysed with FACSuite Software (BD, San Jose, CA). 
 
5.1 APOPTOSIS 
To detect apoptosis rate, was used the following protocol (staining for 
5x105 cells): 
- Cells were washed with PBS ice-cold. 
- Centrifuge at 3000 rpm for 4 min. 
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- Resuspend cells in 93 µl Binding Buffer 1X (HEPES 0,01M, NaCl 
0,14M, CaCl2 2,5mM) and add 1 µl Annexin-V APC conjugated 
- Incubate 10 min at room temperature in the dark 
- Add 400 µl Binding Buffer 1X and acquire 10.000 events 
 
5.2 INTRACELLULAR STAINING 
To stain intracellular proteins, I used the following protocol (staining for 
5x105 cells): 
- Centrifuge cells at 3000 rpm for 5 min and resuspend the pellet in 
100 µl PBS plus 1% BSA and 0,1% NaN3 
- Add 100 µl formaldehyde 4% in PBS and incubate 20 min at room 
temperature 
- Centrifuge cells at 3000 rpm for 5 min 
- Resuspend the pellet in 100 µl PBS plus 0,5% BSA and 0,5% 
Saponin and incubate for 10 min at room temperature 
- Centrifuge cells cells at 3000 rpm for 5 min and resuspend in 40 µl 
PBS plus 1%BSA and 0,1% NaN3 
- Divide the sample in two tubes and add primary antibody (Survivin, 
BCL2, IL-6 and SDF-1α) or matched isotype control. 
- Incubate 1h at 4°C in the dark 
- Add 300 µl PBS plus 0,1% NaN3 and acquire 10.000 events 
 
5.3 SURFACE MARKER STAINING 
To stain surface marker proteins, I used the following protocol (staining for 
2x105 cells): 
- Wash cells with 700 µl PBS plus 2% FBS and 0,1% NaN3 
- Centrifuge cells at 2000 rpm for 4 min 
- Resuspend cell pellet in 40 µl and divide the sample into two tubes 
- Incubate for 10 min at room temperature 
- Add primary antibody (ABCC1) or matched isotype control 
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- Incubate for 45 min in the dark at 4°C 
- Add 300 µl PBS plus 0,1% NaN3 and acquire 10.000 events 
6.WESTERN BLOT 
Whole cell extracts were prepared using a RIPA lysis buffer containing 
50mM Tris-HCl, pH 7.4, 150mM NaCl, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS, 1mM EGTA, 1mM EDTA and the protease 
inhibitors, 50mM NaF, 1mM phenylmethylsulfonyl fluoride (PMSF), 1 mM 
Na3VO4, 2µg/ml aprotinin, 2µg/ml leupeptin: 
- Cells were resuspended in RIPA buffer and incubated for 15 min. 
- The lysate was clarified by centrifugation for 15 min at 4°C. 
- Protein concentration was determined using the Bradford assay 
(Bio-Rad Laboratories). 
- 100 µg whole cell lysate was loaded and run on 8% denaturing 
SDS-PAGE gels. 
- The proteins are transferred to a nitrocellulose membrane (Hybond-
ECL, Amersham Bioscience), and blocked with 5% screamed milk 
in TBS-T (20 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween-20). 
- The membrane was then incubated o.n. at 4°C with the indicated 
primary antibodies as follows: Actin 1:5000 (ThermoFisher), Notch 2 
intracellular domain antibody-cleaved (Asp1733) 1:500 (Sigma-
Aldrich) and Jagged1 1:500 (Santa Cruz Biotechnology). 
- Following washes, the membrane was incubated with HRP-
conjugated species-specific secondary antibodies (Santa-Cruz 
Biotechnology). 
- Proteins were visualized with ECL reagents (Advansta) according to 
the manufacturer’s instructions. 
7. TRANSFECTION AND LUCIFERASE ASSAY 
Intracellular Notch1 (ICN1), also named as ICN1-ΔE because it is lacking 
PEST domain, was previously described by Prof. W.S. (127) (Pear et al., 
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1996). To overexpress ICN2, I used the pADTrack-ICN2 plasmid. For the 
reporter assays, TK-pRL was from Promega Italia s.r.l. (Milano, Italy). The 
pGL3-based plasmid encoding the firelfly luciferase under the control of 13 
repeats of the CSL-responsive element (13XCSL) was as described by 
Shawber C., et al. (32). 
Experiments were carried out as follow: 
- HEK293 were plated in 48-well plate, 60.000/cell per well in 250 µl 
complete DMEM. 
- After 24h cells were transfected with TurboFect (ThermoFisher) 
according to manufacturer’s instruction and with the following 
amount of plasmids: 
! 0,4 µg 13XCSL 
! 0,02 µg TK-pRL 
! 0,044 µg ICN1-ΔE 
! 0,055 µg ICN2 
- 24h post transfection cells were treated with 100 µM CoCl2. 
- The dual luciferase assay was performed according to the 
manufacturer’s directions (Dual-Luciferase® Reporter Assay 
System, Promega). TK-pRL plasmid was used to control 
transfection efficiency 
8. PRIMARY SAMPLES 
8.1 PRIMARY CD138+ MM CELLS ISOLATION 
Primary CD138+ MM cells were isolated from bone marrow (BM) aspirates 
of MM patients and immunomagnetically sorted using EasySep™ Human 
CD138 Positive Selection Kit (Stem Cell Technology) according to 
manufacturer’s instruction. 
 
8.2 PRIMARY CD138+ MM CELLS LENTIVIRAL TRANSFECTION 
Lentiviral infection of primary CD138+ MM cells were carried out as follow: 
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• Primary CD138+ MM cells were resuspended either in lentiviral 
surnatant pLL3.7-empty or pLL3.7-shRNA anti-Jagged1/2 and add: 
! 12 µg/mL Polybrene 
! 20 ng/mL IL-6 in 0,1% BSA 
! 20 ng/mL GMCSF in 0,1% BSA 
! 100 ng/mL IGF-1 in 0,1% BSA 
• After 24h infection, cells were centrifugated, resuspended in 
RPMI1640 full and plated on BMSCs monolayer 
 
8.3 PRIMARY BMSC ISOLATION, CHARACTERIZATION AND 
STAINING 
Primary BMSCs were isolated starting from the negative fraction of primary 
CD138+ MM cells isolation. Negative fraction was plated in T75 flask and 
after 24-48h the medium was changed and the first population of cells that 
are attached to the flask are primary BMSCs. 
BMSCs were characterized both by flow cytometry for CD45, CD14, CD90 
and CD105 expression and by morphological shape by optical microscopy. 
Primary BMSCs growth adherent in complete DMEM medium (Sigma-
Aldrich Co., St Louis, MO, USA), supplemented with 10% (v/v) FBS (Gibco, 
Rockville, MD, USA), 2 mM L-glutamine (Invitrogen Corporation Carlsbad, 
CA, USA), 100 U/ml penicillin   and 100 µg/ml streptomycin. The serum 
was de-complemented for 30’ at 56°C before use. Cells were cultured in 
5% CO2 at 37°C, with complete change of medium every two days. 
For co-cultures set-up, primary BMSCs were stained with PKH26 (Sigma-
Aldrich St Louis, MO), which is a lipophilic dye, to allow the detection of 
BMSCs and primary CD138+ MM cells by flow cytometry. 
The protocol for PKH26 is as follow (staining for 107 cells): 
- Wash cells with serum-free media and centrifuge at 1000 rpm for 5 
min. 
 103 
- The pellet was resuspended in 1 ml of “Diluent C” (Sigma-Aldrich 
Co., St Louis, MO) + 1 µl of PKH26 dye solution (Sigma-Aldrich Co., 
St Louis, MO). 
- Cells were stained for 5 min at RT and the reaction was blocked by 
adding 1 ml of FBS. 
- Cells were washed one times with complete culture medium and 
plated at desidered concentration. 
8.4 CO-CULTURES SET UP 
Transduced primary CD138+ MM cells were plated on BMSCs monolayer in 
48-well plate and treated with 8 nM Bortezomib or vehicle (DMSO) for 24h 
hours. At the end of the treatment apoptosis rate of primary CD138+ cells 
were assessed by FC as Annexin-V+ cells. 
9. STATISTICAL ANALYSIS 
Data are represented as mean ± SD of at least 3 independent experiments. 
Statistical analysis on gene expression analysis and luciferare experiments 
were performed using two-tailed Student's t-test to compare the means of 
normally distributed values and in drug resistance co-culture experiments 
of both in vitro and ex vivo systems and in CD138 expression variation, I 
performed analysis of variance by a one-way ANOVA or two-way ANOVA 
with Tukey’s post-test. 
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